

SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50474/017002

Serial No.

10/626,914

**Applicant** INFORMATION DISCLOSURE

Filing Date

July 25, 2003

Anan Chuntharapai et al.

STATEMENT BY APPLICANT

(Use several sheets if necessary)

Group

1644

(37 C.F.R. § 1.98(b))

**IDS Filed** 

August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	lwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	lwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
9 <del>, v</del>	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
- <del>1</del>	5,540,926	Jul. 30, 1996	Aruffo et al.
78-2	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
_	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER	AMINER DATE CONSIDERED		

**EXAMINER** 

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
STATEMENT	F BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

5,652,353       Jul. 29, 1997       Fiers et al.         5,677,180       Oct. 14, 1997       Robinson et al.         5,721,108       Feb. 24, 1998       Robinson et al.         5,736,137       Apr. 7, 1998       Anderson et al.         5,776,456       Jul. 7, 1998       Anderson et al.         5,808,029       Sep. 15, 1998       Brockhaus et al.         5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,287,537       Sep. 11, 2001       Kaminski et al.	U.S. PATENT DOCUMENTS			
5,721,108       Feb. 24, 1998       Robinson et al.         5,736,137       Apr. 7, 1998       Anderson et al.         5,776,456       Jul. 7, 1998       Anderson et al.         5,808,029       Sep. 15, 1998       Brockhaus et al.         5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,849,898       Dec. 1, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,652,353	Jul. 29, 1997	Fiers et al.	
5,736,137       Apr. 7, 1998       Anderson et al.         5,776,456       Jul. 7, 1998       Anderson et al.         5,808,029       Sep. 15, 1998       Brockhaus et al.         5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,174,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,242,195       Jun. 5, 2001       Idusogie et al.	5,677,180	Oct. 14, 1997	Robinson et al.	
5,776,456       Jul. 7, 1998       Anderson et al.         5,808,029       Sep. 15, 1998       Brockhaus et al.         5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,721,108	Feb. 24, 1998	Robinson et al.	
5,808,029       Sep. 15, 1998       Brockhaus et al.         5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,843,439       Dec. 1, 1998       Anderson et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,736,137	Apr. 7, 1998	Anderson et al.	
5,821,337       Oct. 13, 1998       Carter et al.         5,843,398       Dec. 1, 1998       Kaminski et al.         5,843,439       Dec. 15, 1998       Anderson et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,776,456	Jul. 7, 1998	Anderson et al.	
5,843,398       Dec. 1, 1998       Kaminski et al.         5,843,439       Dec. 1, 1998       Anderson et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,808,029	Sep. 15, 1998	Brockhaus et al.	
5,843,439       Dec. 1, 1998       Anderson et al.         5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,821,337	Oct. 13, 1998	Carter et al.	
5,849,898       Dec. 15, 1998       Seed et al.         6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,843,398	Dec. 1, 1998	Kaminski et al.	
6,015,542       Jan. 18, 2000       Kaminski et al.         6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,843,439	Dec. 1, 1998	Anderson et al.	
6,090,365       Jul. 18, 2000       Kaminski et al.         6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	5,849,898	Dec. 15, 1998	Seed et al.	
6,120,767       Sep. 19, 2000       Robinson et al.         6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	6,015,542	Jan. 18, 2000	Kaminski et al.	
6,171,586       Jan. 9, 2001       Lam et al.         6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	6,090,365	Jul. 18, 2000	Kaminski et al.	
6,171,787       Jan. 9, 2001       Wiley         6,194,551       Feb. 27, 2001       Idusogie et al.         6,224,866       May 1, 2001       Barbera-Guillem         6,242,195       Jun. 5, 2001       Idusogie et al.	6,120,767	Sep. 19, 2000	Robinson et al.	
6,194,551 Feb. 27, 2001 Idusogie et al. 6,224,866 May 1, 2001 Barbera-Guillem 6,242,195 Jun. 5, 2001 Idusogie et al.	6,171,586	Jan. 9, 2001	Lam et al.	
6,224,866 May 1, 2001 Barbera-Guillem 6,242,195 Jun. 5, 2001 Idusogie et al.	6,171,787	Jan. 9, 2001	Wiley	
6,242,195 Jun. 5, 2001 Idusogie et al.	6,194,551	Feb. 27, 2001	Idusogie et al.	
<del></del>	6,224,866	May 1, 2001	Barbera-Guillem	
6,287,537 Sep. 11, 2001 Kaminski et al.	6,242,195	Jun. 5, 2001	Idusogie et al.	
	6,287,537	Sep. 11, 2001	Kaminski et al.	
6,297,022 Oct. 2, 2001 McDonnell et al.	6,297,022	Oct. 2, 2001	McDonnell et al.	
6,297,367 Oct. 2, 2001 Tribouley	6,297,367	Oct. 2, 2001	Tribouley	
6,306,393 Oct. 23, 2001 Goldenberg	6,306,393	Oct. 23, 2001	Goldenberg	
6,355,782 Mar. 12, 2002 Zonana et al.	6,355,782	Mar. 12, 2002	Zonana et al.	

EXA	NIN	<b>NER</b>
-----	-----	------------

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFIC		Serial No.	10/626,914
INFORMATION DISCLOSURE		Applicant	Anan Chuntharapai et al.
STATEMENT	BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
 6,368,596	Apr. 9, 2002	Ghetie et al.	
6,399,061	Jun. 4, 2002	Anderson et al.	
6,403,770	Jun. 11, 2002	Yu et al.	
6,410,391	Jun. 25, 2002	Zelsacher	
6,440,694	Aug. 27, 2002	Bienkowski et al.	
6,455,043	Sep. 24, 2002	Grillo-Lopez	
6,475,986	Nov. 5, 2002	Aggarwal	
6,475,987	Nov. 5, 2002	Shu	
6,506,882	Jan. 14, 2003	Yu et al.	
6,509,170	Jan. 21, 2003	Yu et al.	
6,528,624	Mar. 4, 2003	Idusogie et al.	
6,538,124	Mar. 25, 2003	Idusogie et al.	
6,541,224	Apr. 1, 2003	Yu et al.	
6,551,795	Apr. 22, 2003	Rubenfield et al.	
6,565,827	May 20, 2003	Kaminski et al.	
6,652,852	Nov. 25, 2003	Robinson et al.	
6,682,734	Jan. 27, 2004	Anderson et al.	
6,869,605	Mar. 22, 2005	Browning et al.	
6,875,846	Apr. 5, 2005	Rennert et al.	
7,083,785	Aug. 1, 2006	Browning et al.	
2001/0018041	Aug. 30, 2001	Hanna et al.	
2002/0004587	Jan. 10, 2002	Miller et al.	
2002/0006404	Jan. 17, 2002	Hanna et al.	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
INFORMATION DISCLOSURE		Applicant	Anan Chuntharapai et al.
STATEMEN	T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644 .
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS			
20	002/0009427	Jan. 24, 2002	Wolin et al.	
20	002/0009444	Jan. 24, 2002	Grillo-Lopez	
20	002/0012665	Jan. 31, 2002	Hanna	
20	002/0037852	Mar. 28, 2002	Browning et al.	
20	002/0041847	Apr. 11, 2002	Goldenberg	
20	002/0058029	May 16, 2002	Hanna	
20	002/0081296	Jun. 27, 2002	Theill et al.	
20	002/0086018	Jul. 4, 2002	Theill et al.	
26	002/0128488	Sep. 12, 2002	Yamakawa et al.	
26	002/0136719	Sep. 26, 2002	Shenoy et al.	
. 20	002/0165156	Nov. 7, 2002	Browning et al.	
20	002/0172674	Nov. 21, 2002	Browning et al.	
20	002/0197255	Dec. 26, 2002	Anderson et al.	
20	002/0197256	Dec. 26, 2002	Grewal	
26	003/0012783	Jan. 16, 2003	Kindsvogel	
20	003/0021781	Jan. 30, 2003	Anderson et al.	
20	003/0023038	Jan. 30, 2003	Rennert et al.	
20	003/0026801	Feb. 6, 2003	Weiner et al.	
20	003/0068664	Apr. 10, 2003	Albitar et al.	
20	003/0082172	May 1, 2003	Anderson et al.	
20	003/0082175	May 1, 2003	Schneider et al.	
20	003/0092164	May 15, 2003	Gross et al.	
20	003/0095963	May 22, 2003	Anderson et al.	
· · · · · · · · · · · · · · · · · · ·				

**EXAMINER** 

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMME		Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
STATEMENT	F BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
2003/0095967	May 22, 2003	MacKay et al.	
2003/0099990	May 29, 2003	Hsu	
2003/0103971	Jun. 5, 2003	Hariharan et al.	
2003/0133930	Jul. 17, 2003	Goldenberg et al.	
2003/0147885	Aug. 7, 2003	Anderson et al.	
2003/0157108	Aug. 21, 2003	Presta	
2003/0180292	Sep. 25, 2003	Hanna et al.	
2003/0185796	Oct. 2, 2003	Wolin et al.	
2003/0194743	Oct. 16, 2003	Beltzer et al.	
2003/0219433	Nov. 27, 2003	Hansen et al.	
2003/0219818	Nov. 27, 2003	Bohen et al.	
2004/0093621	May 13, 2004	Shitara et al.	
2005/0070689	Mar. 31, 2005	Dixit et al.	
2005/0095243	May 5, 2005	Chan et al.	
2005/0163775	Jul. 28, 2005	Chan et al.	
2006/0073146	Apr. 6, 2006	Ashkenazi et al.	
2006/0240517	Oct. 26, 2006	Ambrose et al.	
2006/0240519	Oct. 26, 2006	Ambrose et al.	
2006/0240520	Oct. 26, 2006	Ambrose et al.	
09/724,341	Nov. 28, 2000	Ashkenazi et al.	

<b>EXAMINER</b>
-----------------

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION BISSI OSUPE		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
-	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	1
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DIGGLOGUES		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 98/55620 A1	Dec. 10, 1998	WIPO	
WO 98/55621 A1	Dec. 10, 1998	WIPO	
WO 98/56418 A1	Dec. 17, 1998	WIPO	
WO 98/58964 A1	Dec. 30, 1998	WIPO	
WO 99/00518 A1	Jan. 7, 1999	WIPO	
WO 99/02653 A1	Jan. 21, 1999	WIPO	
WO 99/04001 A1	Jan. 28, 1999	WIPO .	
WO 99/07738 A2	Feb. 18, 1999	WIPO	
WO 99/09165 A1	Feb. 25, 1999	WIPO	
WO 99/11791 A2	Mar. 11, 1999	WIPO	
WO 99/12964 A2	Mar. 18, 1999	WIPO	
WO 99/12965 A2	Mar. 18, 1999	WIPO	
WO 99/19490 A1	Арг. 22, 1999	WIPO	
WO 99/22764 A1	May 14, 1999	WIPO	
WO 99/28462 A2	Jun. 10, 1999	WIPO	
WO 99/33980 A2	Jul. 8, 1999	WIPO	
WO 99/33988 A1	Jul. 8, 1999	WIPO ·	
WO 99/35170 A2	Jul. 15, 1999	WIPO	
WO 99/50416 A1	Oct. 7, 1999	WIPO	
WO 99/51642 A1	Oct. 14, 1999	WIPO	

EXAM	INER
------	------

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)  PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 00/09160 A1	Feb. 24, 2000	WIPO	
WO 00/20864 A1	Apr. 13, 2000	WIPO	
WO 00/24811 A1	May 4, 2000	WIPO	
WO 00/26244 A2	May 11, 2000	WIPO	
WO 00/27428 A1	May 18, 2000	WIPO	
WO 00/27433 A1	May 18, 2000	WIPO	
WO 00/39295 A1	Jul. 6, 2000	WIPO	
WO 00/42072 A2	Jul. 20, 2000	-WIPO	
WO 00/43032 A2	Jul. 27, 2000	WIPO	
WO 00/44788 A1	Aug. 3, 2000	WIPO	
WO 00/45836 A1	Aug. 10, 2000	WIPO	
WO 00/50597 A2	Aug. 31, 2000	WIPO	
WO 00/50633 A1	Aug. 31, 2000	WIPO	
WO 00/58362 A1	Oct. 5, 2000	WIPO	
WO 00/67795 A1	Nov. 16, 2000	WIPO	
WO 00/67796 A1	Nov. 16, 2000	WIPO	
WO 00/68378 A1	Nov. 16, 2000	WIPO	
WO 00/74718 A1	Dec. 14, 2000	WIPO	
WO 00/76542 A1	Dec. 21, 2000	WIPO	
WO 01/03734 A1	Jan. 18, 2001	WIPO	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)  PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO 01/10460 A1	Feb. 15, 2001	WIPO ·
	WO 01/10461 A1	Feb. 15, 2001	WIPO
	WO 01/10462 A1	Feb. 15, 2001	WIPO
	WO 01/12812 A2	Feb. 22, 2001	WIPO
	WO 01/13945 A1	Mar. 1, 2001	WIPO
	WO 01/24811 A1	Apr. 12, 2001	WIPO
	WO 01/25256 A2	Apr. 12, 2001	WIPO
	WO 01/34194 A1	May 17, 2001	WIPO
	WO 01/58949 A2	Aug. 16, 2001	WIPO
	WO 01/60397 A1	Aug. 23, 2001	WIPO
	WO 01/72333 A1	Oct. 4, 2001	WIPO
	WO 01/74388 A1	Oct 11, 2001	WIPO
	WO 01/77342 A1	Oct. 18, 2001	WIPO
	WO 01/80844 A2	Nov. 1, 2001	WIPO
	WO 01/96528 A2	Dec. 20, 2001	WIPO
	WO 01/97858 A2	Dec. 27, 2001	WIPO
	WO 02/02641 A1	Jan. 10, 2002	WIPO
	WO 02/04021 A1	Jan. 17, 2002	WIPO
	WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)
	WO 02/16412 A2	Feb. 28, 2002	WIPO

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATE	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914  Anan Chuntharapai et al.  July 25, 2003
INFORMATI	ON DIGGLOCUPE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN F	PATENT OR PUBLISH	IED FOREIGN PATENT APPLICATION
	WO 02/18620 A2	Mar. 7, 2002	WIPO
	WO 02/24909 A2	Mar. 28, 2002	WIPO
	WO 02/34790 A1	May 2, 2002	WIPO
	WO 02/38766 A2	May 16, 2002	WIPO
	WO 02/060485 A2	Aug. 8, 2002	WIPO
	WO 02/060955 A2	Aug. 8, 2002	WIPO
	WO 02/079255 A1	Oct. 10, 2002	WIPO
-	WO 02/092620 A2	Nov. 21, 2002	WIPO
	WO 02/094192 A2	Nov. 28, 2002	WIPO
	WO 02/094852 A2	Nov. 28, 2002	WIPO
	WO 02/096948 A2	Dec. 5, 2002	WIPO
	WO 02/102312 A2	Dec. 27, 2002	WIPO
	WO 03/002607 A1	Jan. 9, 2003	WIPO
	WO 03/014294 A2	Feb. 20, 2003	WIPO
	WO 03/024991 A2	Mar. 27, 2003	WIPO
	WO 03/033658 A2	Apr. 24, 2003	WIPO
	WO 03/035846 A2	May 1, 2003	WIPO
	WO 03/045421 A1	Jun. 5, 2003	WIPO
	WO 03/049694 A2	Jun. 19, 2003	WIPO
	WO 03/055979 A2	Jul. 10, 2003	WIPO

EXAMINER DATE CONSIDERED
--------------------------

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002 10/626,914 Anan Chuntharapai et al. July 25, 2003
	PATENT AND TRADEMARK OFFICE	Serial No.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN F	PATENT OR PUBLIS	HED FOREIGN PATENT APPLICATION
WO 03/061694 A1	Jul. 31, 2003	WIPO
WO 03/068821 A2	Aug. 21, 2003	WIPO
WO 2004/011611 A2	Feb. 5, 2004	WIPO
WO 2004/032828 A2	Apr. 22, 2004	WIPO
WO 2004/035607 A2	Apr. 29, 2004	WIPO
WO 2004/056312 A2	Jul. 8, 2004	WIPO
WO 2004/081043 A2	Sep. 23, 2004	WIPO
WO 2005/000351 A2	Jan. 6, 2005	WIPO
WO 2005/005462 A2	Jan. 20, 2005	WIPO
WO 2006/052493 A1	May 18, 2006	WIPO
WO 2006/068867 A1	May 29, 2006	WIPO
WO 2006/073941 A2	Jul. 13, 2006	WIPO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	n if not in conformance and not considered. Include conv. of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644 ·
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

-	
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
	Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
	Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
	Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
	Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
	Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
	Baldwin, "The NF-κB and IκB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
	Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
	Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
	Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
	Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
	Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
	Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
	Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
	Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
	Callard et al., "CD40 ligand and its role in X-linked hyper-lgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
NIEGOMATIC	NA BIOGLOGUES	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Investigation 54:26-31 (1986).
	Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
	Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum</i> . 44:1313-9 (2001).
_	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
	Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
	Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
	Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666 (1980).
-	Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
	Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
	Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
	Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ, Eur. J. Immunol. 17:689-93 (1987).
	Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
	Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL recept family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
	De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
	Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
	Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: th IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INCORMATIO	N DICCI COURT	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Use several si	leets ii flecessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," <i>Science</i> 261:1328-30 (1993).
	Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
	Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," Rheumatology 40:205-11 (2001).
	Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
	Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
	Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
	Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," J. Exp. Med. 180:157-63 (1994).
	Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
	Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
	Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
	GenBank accession number AF046888
	GenBank accession number AF136293
	GenBank accession number AK008142
,	GenBank accession number Al250289, XP002206618
	GenBank accession number Z99716.4, XP002206619
	Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
	Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

	EXAMINER	DATE CONSIDERED
ì		<del></del>

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON DISCH OCHES	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Ose several)	sneets ii necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

-	
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," Cell 73:447-56 (1993).
	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
	Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
	Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
	Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
	Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
	Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
	Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
	Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," <i>Science</i> 273:1864-7 (1996).
	Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
	Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," <i>J. Exp. Med.</i> 188:1185-90 (1998).
	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
	Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
	Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," Genome Res. 10:237-43 (2000).
	Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATI	ON DISCUOSURE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Ose several s	neets ii necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).  Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).  Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFa J. Biol. Chem. 264:14927-34 (1989).  Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).  Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		
262:905-7 (1993).  Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).  Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab." Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).  Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," <i>Immunogenetics</i> 51:924-9 (2000).  Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFa <i>J. Biol. Chem.</i> 264:14927-34 (1989).  Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," <i>Agents Actions</i> 19:295-305 (1986). Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," <i>Science</i> 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Mol. Immunol.</i> 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor <i>Mol. Cell</i> 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," <i>J. Biol. Chem.</i> 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <i>J. Immunol.</i> 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," <i>Cell</i> 66:233-43 (1991).		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
226:889-96 (1992).		
Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).  Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).  Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFa J. Biol. Chem. 264:14927-34 (1989).  Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).  Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		
Immunogenetics 51:924-9 (2000).  Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFa J. Biol. Chem. 264:14927-34 (1989).  Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).  Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor & Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US01/2807, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
J. Biol. Chem. 264:14927-34 (1989).  Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).  Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).	-	
Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).  Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 9 Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," J. Biol. Chem. 264:14927-34 (1989).
Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 9 Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
Immunol. 28:1027-37 (1991).  Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor & Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		
Mol. Cell 4:563-71 (1999).  Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).  Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		
Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).  International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.  International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.  International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		
International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006  Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).		International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
Cell 66:233-43 (1991).		International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
lackson et al. "In vitro antibody maturation; improvement of a high affinity, neutralizing antibody against II -18."		
Immunol. 154:3310-9 (1995).		Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).		Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

EXAMINER	DATE CONSIDERED
EYAMINED: Initial citation considered. Draw line through citation	if not in conformance and not concidered. Include conv. of this

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATIC	AN DICCLOCUPE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Ose several si	neets ii necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

<del></del>
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum</i> . 39:797-809 (1996).
Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).
Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," <i>Trends Immunol.</i> 22:61-3 (2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," Leuk. Res. 11:1119-25 (1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	DATE CONSIDERED
EXAMINED: Initial citation considered. Draw line through citation if not in conformance and not considered. Include conv. of this	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002	
(MODIFIED)	(MODIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
Kwon et al., "Single amino acid substitutions of α₁-antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," <i>Curr. Opin. Immunol.</i> 11:340-5 (1999).
 Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
Lane et al., "B cell function in mice transgenic for mCTLA-Hγ1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," J. Exp. Med. 179:819-30 (1994).
Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum</i> . 46:2673-7 (2002).
Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," <i>Arthritis Rheum.</i> 44:S370, Abstract No. 1905 (2001).
 Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
 Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the AWySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
	<del>-</del>

SUBSTITUTE FORM PTO-1449	UBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE		50474/017002
(MODIFIED)	(MODIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHO	DR, TITLE, DATE, PLACE OF PUBLICATION)
	Lentz et al., "Bcmd decreases the life span of B (1998).	-2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7
	Lesley et al., "Reduced competitiveness of auto- Immunity 20:441-53 (2004).	antigen-engaged B cells due to increased dependence on BAFF,
	Levine and Pestronk, "IgM antibody-related poly Neurology 52:1701-4 (1999).	rneuropathies: B-cell depletion chemotherapy using rituximab,"
	Lewis et al., "Cloning and expression of cDNAs demonstrate one receptor is species specific," F	for two distinct murine tumor necrosis factor receptors Proc. Natl. Acad. Sci. USA 88:2830-4 (1991).
	Linsley et al., "Immunosuppression in vivo by a s 257:792-5 (1992).	soluble form of the CTLA-4 T cell activation molecule," Science
	Locksley et al., "The TNF and TNF receptor sup (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501
	Loetscher et al., "Molecular cloning and express 61:351-9 (1990).	sion of the human 55 kd tumor necrosis factor receptor," Cell
	Lotz et al., "The nerve growth factor/tumor necro	osis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).
	MacFarlane et al., "Identification and molecular Biol. Chem. 272:25417-20 (1997).	cloning of two novel receptors for the cytotoxic ligand TRAIL," J.
<del></del>	Mackay and Browning, "BAFF: a fundamental so	urvival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002).
Mackay et al., "Mice transgenic for BAFF develop lymphocytic disorders along with autoin J. Exp. Med. 190:1697-710 (1999).		p lymphocytic disorders along with autoimmune manifestations,"
	Mackay et al., "BAFF and APRIL: a tutorial on B	cell survivat," Annu. Rev. Immunol. 21:231-64 (2003).
	MacLennan, "Germinal centers," Annu. Rev. Imi	munol. 12:117-39 (1994).
Madry et al., "The characterization of murine BCMA gene defines it as a new member of the factor receptor superfamily," <i>Int. Immunol.</i> 10:1693-702 (1998).  Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheu <i>Immunol. Rev.</i> 144:195-223 (1995).		
		a probe of pathogenesis and therapy of rheumatoid disease,"
	Mallett et al., "Characterization of the MRC OX4 related to nerve growth factor receptor," EMBO.	0 antigen of activated CD4 positive T lymphocytes – a molecule J. 9:1063-8 (1990).
	Mandala et al., "Alteration of lymphocyte trafficki 296:346-9 (2002).	ing by sphingosine-1-phosphate receptor agonists," Science
EXAMINER	<del></del>	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449			50474/017002
(MODIFIED)			10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κΒ," <i>Curr. Biol.</i> 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-kB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4 <sup>+</sup> T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i> 84:817-25 (1988).
 I to the second

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		50474/017002
(MODIFIED)			10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH₂-terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," Blood 97:198-204 (2001).
Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett 424:41-5 (1998).
Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," J. Biol. Chem. 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
	Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," <i>Eur. J. Immunol.</i> 18:1397-404 (1988).
	Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immunol. 31:213-24 (1990).
	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
	Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
	Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
-	Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
	Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
	Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," <i>J. Exp. Med.</i> 197:297-302 (2003).
	Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 (1990).
	Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
	Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," Science 293:2111-4 (2001).
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 169:147-55 (1996).
	Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," <i>Proc. Natl. Acad. Sci. USA</i> 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
	· · · · · · · · · · · · · · · · · · ·

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
 Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," J. Exp. Med. 189:1747-56 (1999).
Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
 Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," <i>Science</i> 277:818-21 (1997).
Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," J. Biol. Chem. 276:6591-604 (2001).
Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," <i>Proc. Natl. Acad. Sci. USA</i> 97:9156-61 (2000).
Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell 89:309-19 (1997).
Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
 Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
 Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
 Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).
 I

EXA	MINER
-----	-------

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
	Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," <i>Cell</i> 66:1133-44 (1991).
	Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
	Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
	Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
	Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
	Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
-	Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
	Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
	Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
	Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
	Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
-	Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," <i>J. Biol. Chem.</i> 264:11282-7 (1989).

ı	=)	(A	M	IN	ΕR	

(Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Group	1644
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-kB/lkB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," <i>Science</i> 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," Arthritis Rheum. 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," <i>Virology</i> 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include conv of this		

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem. 262:4429-32 (1987).
Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," Curr. Biol. 11:1547-52 (2001).
Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
 Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EXAMINER	DATE CONSIDERED



SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No. 5

50474/017002

Serial No.

10/626,914

Applicant INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Use several sheets if necessary)

Filing Date

July 25, 2003

Anan Chuntharapai et al.

Group

1644

(37 C.F.R. § 1.98(b))

IDS Filed

August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	lwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	lwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
	5,540,926	Jul. 30, 1996	Aruffo et al.
	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER			DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS			
5,652,353	Jul. 29, 1997	Fiers et al.		
5,677,180	Oct. 14, 1997	Robinson et al.		
5,721,108	Feb. 24, 1998	Robinson et al.		
5,736,137	Apr. 7, 1998	Anderson et al.		
5,776,456	Jul. 7, 1998	Anderson et al.		
5,808,029	Sep. 15, 1998	Brockhaus et al.		
5,821,337	Oct. 13, 1998	Carter et al.		
5,843,398	Dec. 1, 1998	Kaminski et al.		
5,843,439	Dec. 1, 1998	Anderson et al.		
5,849,898	Dec. 15, 1998	Seed et al.		
6,015,542	Jan. 18, 2000	Kaminski et al.		
6,090,365	Jul. 18, 2000	Kaminski et al.		
6,120,767	Sep. 19, 2000	Robinson et al.		
6,171,586	Jan. 9, 2001	Lam et al.		
6,171,787	Jan. 9, 2001	Wiley		
6,194,551	Feb. 27, 2001	Idusogie et al.		
6,224,866	May 1, 2001	Barbera-Guillem		
6,242,195	Jun. 5, 2001	Idusogie et al.		
6,287,537	Sep. 11, 2001	Kaminski et al.		
6,297,022	Oct. 2, 2001	McDonnell et al.		
6,297,367	Oct. 2, 2001	Tribouley		
6,306,393	Oct. 23, 2001	Goldenberg		
6,355,782	Mar. 12, 2002	Zonana et al.		

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS			
	6,368,596	Apr. 9, 2002	Ghetie et al.	
	6,399,061	Jun. 4, 2002	Anderson et al.	
	6,403,770	Jun. 11, 2002	Yu et al.	
	6,410,391	Jun. 25, 2002	Zelsacher	
	6,440,694	Aug. 27, 2002	Bienkowski et al.	
	6,455,043	Sep. 24, 2002	Grillo-Lopez	
	6,475,986	Nov. 5, 2002	Aggarwal	
	6,475,987	Nov. 5, 2002	Shu	
	6,506,882	Jan. 14, 2003	Yu et al.	
	6,509,170	Jan. 21, 2003	Yu et al.	
	6,528,624	Mar. 4, 2003	Idusogie et al.	
	6,538,124	Mar. 25, 2003	Idusogie et al.	
	6,541,224	Apr. 1, 2003	Yu et al.	
	6,551,795	Apr. 22, 2003	Rubenfield et al.	
	6,565,827	May 20, 2003	Kaminski et al.	
	6,652,852	Nov. 25, 2003	Robinson et al.	
	6,682,734	Jan. 27, 2004	Anderson et al.	
	6,869,605	Mar. 22, 2005	Browning et al.	
	6,875,846	Apr. 5, 2005	Rennert et al.	
	7,083,785	Aug. 1, 2006	Browning et al.	
	2001/0018041	Aug. 30, 2001	Hanna et al.	
	2002/0004587	Jan. 10, 2002	Miller et al.	
_	2002/0006404	Jan. 17, 2002	Hanna et al.	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
2002/0009427	Jan. 24, 2002	Wolin et al.
2002/0009444	Jan. 24, 2002	Grillo-Lopez
2002/0012665	Jan. 31, 2002	Hanna
2002/0037852	Mar. 28, 2002	Browning et al.
2002/0041847	Apr. 11, 2002	Goldenberg
2002/0058029	May 16, 2002	Hanna
2002/0081296	Jun. 27, 2002	Theill et al.
2002/0086018	Jul. 4, 2002	Theill et al.
2002/0128488	Sep. 12, 2002	Yamakawa et al.
2002/0136719	Sep. 26, 2002	Shenoy et al.
2002/0165156	Nov. 7, 2002	Browning et al.
2002/0172674	Nov. 21, 2002	Browning et al.
2002/0197255	Dec. 26, 2002	Anderson et al.
2002/0197256	Dec. 26, 2002	Grewal
2003/0012783	Jan. 16, 2003	Kindsvogel
2003/0021781	Jan. 30, 2003	Anderson et al.
2003/0023038	Jan. 30, 2003	Rennert et al.
2003/0026801	Feb. 6, 2003	Weiner et al.
2003/0068664	Apr. 10, 2003	Albitar et al.
2003/0082172	May 1, 2003	Anderson et al.
2003/0082175	May 1, 2003	Schneider et al.
2003/0092164	May 15, 2003	Gross et al.
2003/0095963	May 22, 2003	Anderson et al.

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 L	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	AN DIGGLOCALIDE	Applicant	Anan Chuntharapai et al.
STATEMENT	ON DISCLOSURE  BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
2003/0095967	May 22, 2003	MacKay et al.
2003/0099990	May 29, 2003	Hsu
2003/0103971	Jun. 5, 2003	Hariharan et al.
2003/0133930	Jul. 17, 2003	Goldenberg et al.
2003/0147885	Aug. 7, 2003	Anderson et al.
2003/0157108	Aug. 21, 2003	Presta
2003/0180292	Sep. 25, 2003	Hanna et al.
2003/0185796	Oct. 2, 2003	Wolin et al.
2003/0194743	Oct. 16, 2003	Beltzer et al.
2003/0219433	Nov. 27, 2003	Hansen et al.
2003/0219818	Nov. 27, 2003	Bohen et al.
2004/0093621	May 13, 2004	Shitara et al.
2005/0070689	Mar. 31, 2005	Dixit et al.
2005/0095243	May 5, 2005	Chan et al.
2005/0163775	Jul. 28, 2005	Chan et al.
2006/0073146	Apr. 6, 2006	Ashkenazi et al.
2006/0240517	Oct. 26, 2006	Ambrose et al.
2006/0240519	Oct. 26, 2006	Ambrose et al.
2006/0240520	Oct. 26, 2006	Ambrose et al.
09/724,341	Nov. 28, 2000	Ashkenazi et al.

EXAMINER
----------

(Ose several sneets if flecessary)  (37 C.F.R. § 1.98(b))		Group IDS Filed	1644 August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
	011 B1001 001 IB5	Applicant	Anan Chuntharapai et al.
(MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449		Attorney Docket No.	50474/017002

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
· · · ·	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 (	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 98/55620 A1	Dec. 10, 1998	WIPO
WO 98/55621 A1	Dec. 10, 1998	WIPO
WO 98/56418 A1	Dec. 17, 1998	WIPO
WO 98/58964 A1	Dec. 30, 1998	WIPO
WO 99/00518 A1	Jan. 7, 1999	WIPO
WO 99/02653 A1	Jan. 21, 1999	WIPO
WO 99/04001 A1	Jan. 28, 1999	WIPO
WO 99/07738 A2	Feb. 18, 1999	WIPO
WO 99/09165 A1	Feb. 25, 1999	WIPO
WO 99/11791 A2	Mar. 11, 1999	WIPO
WO 99/12964 A2	Mar. 18, 1999	WIPO
WO 99/12965 A2	Mar. 18, 1999	WIPO
WO 99/19490 A1	Apr. 22, 1999	WIPO
WO 99/22764 A1	May 14, 1999	WIPO
 WO 99/28462 A2	Jun. 10, 1999	WIPO
WO 99/33980 A2	Jul. 8, 1999	WIPO
WO 99/33988 A1	Jul. 8, 1999	WIPO
WO 99/35170 A2	Jul. 15, 1999	WIPO
WO 99/50416 A1	Oct. 7, 1999	WIPO
WO 99/51642 A1	Oct. 14, 1999	WIPO

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO 00/09160 A1	Feb. 24, 2000	WIPO	
	WO 00/20864 A1	Apr. 13, 2000	WIPO	
-	WO 00/24811 A1	May 4, 2000	WIPO	
	WO 00/26244 A2	May 11, 2000	WIPO	
	WO 00/27428 A1	May 18, 2000	WIPO	
	WO 00/27433 A1	May 18, 2000	WIPO	
	WO 00/39295 A1	Jul. 6, 2000	WIPO	
	WO 00/42072 A2	Jul. 20, 2000	·WIPO	
	WO 00/43032 A2	Jul. 27, 2000	WIPO	
	WO 00/44788 A1	Aug. 3, 2000	WIPO	
	WO 00/45836 A1	Aug. 10, 2000	WIPO	
	WO 00/50597 A2	Aug. 31, 2000	WIPO	
	WO 00/50633 A1	Aug. 31, 2000	WIPO	
-	WO 00/58362 A1	Oct. 5, 2000	WIPO	
	WO 00/67795 A1	Nov. 16, 2000	WIPO	
	WO 00/67796 A1	Nov. 16, 2000	WIPO	
	WO 00/68378 A1	Nov. 16, 2000	WIPO	
	WO 00/74718 A1	Dec. 14, 2000	WIPO	
	WO 00/76542 A1	Dec. 21, 2000	WIPO	
	WO 01/03734 A1	Jan. 18, 2001	WIPO	

EXAMINER	DATE CONSIDERED
<del></del>	<del></del>

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	MODIFIED) PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION BIRDLING		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN P	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
WO 01/10460 A1	Feb. 15, 2001	WIPO
WO 01/10461 A1	Feb. 15, 2001	WIPO
WO 01/10462 A1	Feb. 15, 2001	WIPO
WO 01/12812 A2	Feb. 22, 2001	WIPO
WO 01/13945 A1	Mar. 1, 2001	WIPO
WO 01/24811 A1	Apr. 12, 2001	WIPO
WO 01/25256 A2	Apr. 12, 2001	WIPO
WO 01/34194 A1	May 17, 2001	WIPO
WO 01/58949 A2	Aug. 16, 2001	WIPO
WO 01/60397 A1	Aug. 23, 2001	WIPO
WO 01/72333 A1	Oct. 4, 2001	WIPO
WO 01/74388 A1	Oct 11, 2001	WIPO
WO 01/77342 A1	Oct. 18, 2001	WIPO
WO 01/80844 A2	Nov. 1, 2001	WIPO
WO 01/96528 A2	Dec. 20, 2001	WIPO
WO 01/97858 A2	Dec. 27, 2001	WIPO
WO 02/02641 A1	Jan. 10, 2002	WIPO
WO 02/04021 A1	Jan. 17, 2002	WIPO
WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)
WO 02/16412 A2	Feb. 28, 2002	WIPO

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TR	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INTERPLATION PURCHASHIPS		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 02/1862	20 A2 Mar. 7, 200	02 WIPO	
WO 02/2490	09 A2 Mar. 28, 20	002 WIPO	
WO 02/3479	90 A1 May 2, 2002	02 WIPO	
WO 02/3876	66 A2 May 16, 200	002 WIPO	
WO 02/0604	485 A2 Aug. 8, 200	02 WIPO	
WO 02/0609	955 A2 Aug. 8, 200	02 WIPO	
WO 02/0792	255 A1 Oct. 10, 200	002 WIPO	
WO 02/0926	620 A2 Nov. 21, 20	002 WIPO	
WO 02/094	192 A2 Nov. 28, 20	002 WIPO	
WO 02/094	852 A2 Nov. 28, 20	002 WIPO	
WO 02/096	948 A2 Dec. 5, 200	02 WIPO	
WO 02/102	312 A2 Dec. 27, 20	002 WIPO	
WO 03/0026	607 A1 Jan. 9, 2003	03 WIPO	
WO 03/0142	294 A2 Feb. 20, 20	003 WIPO	
WO 03/024	991 A2 Mar. 27, 20	003 WIPO	
WO 03/0336	658 A2 Apr. 24, 200	003 WIPO .	
WO 03/035	846 A2 May 1, 2003	03 WIPO	
WO 03/045	421 A1 Jun. 5, 200	03 WIPO	
WO 03/0496	694 A2 Jun. 19, 200	003 WIPO	
WO 03/0559	979 A2 Jul. 10, 200	03 WIPO	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN F	PATENT OR PUBLISH	HED FOREIGN PATENT APPLICATION
WO 03/061694 A1	Jul. 31, 2003	WIPO
WO 03/068821 A2	Aug. 21, 2003	WIPO
WO 2004/011611 A2	Feb. 5, 2004	WIPO
WO 2004/032828 A2	Apr. 22, 2004	WIPO
WO 2004/035607 A2	Apr. 29, 2004	WIPO
WO 2004/056312 A2	Jul. 8, 2004	WIPO
WO 2004/081043 A2	Sep. 23, 2004	WIPO
WO 2005/000351 A2	Jan. 6, 2005	WIPO
WO 2005/005462 A2	Jan. 20, 2005	WIPO
WO 2006/052493 A1	May 18, 2006	WIPO
WO 2006/068867 A1	May 29, 2006	WIPO
WO 2006/073941 A2	Jul. 13, 2006	WIPO

,	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
	Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
•	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
	Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
Baldwin, "The NF-κB and IκB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," Cell 72:847-56 (1993).
Callard et al., "CD40 ligand and its role in X-linked hyper-lgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)  PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31 (1986).
	Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
	Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
	Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
	Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
	Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666-8 (1980).
	Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
	Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
	Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
	Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ," <i>Eur. J. Immunol.</i> 17:689-93 (1987).
	Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
	Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
	De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
	Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
	Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).
·	A CONTRACT OF THE CONTRACT OF

EXAMINER		DATE CONSIDERED	
	EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include conv of this	

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science 261:1328-30 (1993).
Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
 Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," <i>Rheumatology</i> 40:205-11 (2001).
Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
 Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
GenBank accession number AF046888
GenBank accession number AF136293
GenBank accession number AK008142
GenBank accession number Al250289, XP002206618
GenBank accession number Z99716.4, XP002206619
Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citatio form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON DIGGLOCKIDE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," Cell 73:447-56 (1993).
	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
	Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
	Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
	Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
	Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
	Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
	Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
	Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," Science 273:1864-7 (1996).
	Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
	Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," J. Cell. Biochem. (abstract only) Supplement 15F:113 (P424) (1991).
_	Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
	Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," <i>Genome Res.</i> 10:237-43 (2000).
<u> </u>	Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this

(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Group	1644
		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-7 (1993).
	Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
	Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," J. Biol. Chem. 264:14927-34 (1989).
	Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
	Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).
	Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).
	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
	Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
	Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <i>J. Immunol.</i> 164:4178-84 (2000).
	International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
	International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
	International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
	Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
, , ,	Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).
	I

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATI	ON DIGGLOCUPE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
	Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum</i> . 39:797-809 (1996).
	Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
	Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
	Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
	Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
	Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
	Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
	Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-кB2," <i>Immunity</i> 10:515-24 (2002).
	Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
	Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (2001).
	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," Leuk. Res. 11:1119-25 (1987).
	Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
	Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).
h	<u> </u>

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	a if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
Kwon et al., "Single amino acid substitutions of α <sub>1</sub> -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," Curr. Opin. Immunol. 11:340-5 (1999).
Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
 Lane et al., "B cell function in mice transgenic for mCTLA-Hγ1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
 Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum.</i> 46:2673-7 (2002).
Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," Arthritis Rheum. 44:S370, Abstract No. 1905 (2001).
Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
 Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the AWySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lentz et al., "Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7 (1998).	
	Lesley et al., "Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF Immunity 20:441-53 (2004).	
	Levine and Pestronk, "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab," Neurology 52:1701-4 (1999).	
	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific," <i>Proc. Natl. Acad. Sci. USA</i> 88:2830-4 (1991).	
	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> 257:792-5 (1992).	
	Locksley et al., "The TNF and TNF receptor superfamilies: integrating mammalian biology," Cell 104:487-501 (2001).	
	Loetscher et al., "Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor," Cell 61:351-9 (1990).	
	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).	
	MacFarlane et al., "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-20 (1997).	
	Mackay and Browning, "BAFF: a fundamental survival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002).	
	Mackay et al., "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations," J. Exp. Med. 190:1697-710 (1999).	
	Mackay et al., "BAFF and APRIL: a tutorial on B cell survival," Annu. Rev. Immunol. 21:231-64 (2003).	
	MacLennan, "Germinal centers," Annu. Rev. Immunol. 12:117-39 (1994).	
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," Int. Immunol. 10:1693-702 (1998).	
	Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease," <i>Immunol. Rev.</i> 144:195-223 (1995).	
	Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a molecule related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063-8 (1990).	
	Mandala et al., "Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists," Science 296:346-9 (2002).	
EXAMINER	DATE CONSIDERED	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTM	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

activates apoptosis and NF-kB," <i>Curr. Biol.</i> 6:1669-76 (1996).  Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-kB and AP- <i>J. Biol. Chem.</i> 72:1402-932 (1997).  Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," <i>Curr. Biol.</i> 6:750-2 (1996).  Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-6 (1997).  Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," <i>Curr. Biol.</i> 8:525-8 (1998).  Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462 (1996).  Marthews, "Medical heretics," <i>New Scientist</i> 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69" Annual Scientific Meeting of the American College of RheumatologylAssociate of RheumatologylAs		
activates apoptosis and NF-kB," <i>Curr. Biol.</i> 6:1669-76 (1996).  Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-kB and AP- <i>J. Biol. Chem.</i> 72:1402-932 (1997).  Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," <i>Curr. Biol.</i> 6:750-2 (1996).  Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-6 (1997).  Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," <i>Curr. Biol.</i> 8:525-8 (1998).  Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462 (1996).  Marthews, "Medical heretics," <i>New Scientist</i> 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69" Annual Scientific Meeting of the American College of RheumatologylAssociate of RheumatologylAs		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
interacts with members of the TNFR-associated factor family and activates transcription factors NF-κB and AP- <i>J. Biol. Chem.</i> 272:14029-32 (1997).  Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr.  Biol. 6:750-2 (1996).  Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).  Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).  Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," Nature 382:462 (1996).  Matthews, "Medical heretics," New Scientist 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," Immunity 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," J. Immunol. 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).  Moore et al., "Abnormalities in CD4" T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med	,	Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-кВ," <i>Curr. Biol.</i> 6:1669-76 (1996).
Biol. 6:750-2 (1996).  Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).  Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).  Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," Nature 382:462 (1996).  Matthews, "Medical heretics," New Scientist 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," Immunity 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature 348:552 (1990).  McKay et al., "Belimurnab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatolog Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," J. Immunol. 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).  More et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260 (1999).		interacts with members of the TNFR-associated factor family and activates transcription factors NF-kB and AP-1,"
(1997).  Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," <i>Curr. Biol.</i> 8:525-8 (1998).  Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462 (1996).  Matthews, "Medical heretics," <i>New Scientist</i> 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).		
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462 (1996).  Matthews, "Medical heretics," <i>New Scientist</i> 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69" Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology-Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).		
and TACI," Curr. Biol. 10:785-8 (2000).  Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," Nature 382:462 (1996).  Matthews, "Medical heretics," New Scientist 170:34-7 (2001).  Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," Immunity 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," J. Immunol. 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med		
<ul> <li>(1996).</li> <li>Matthews, "Medical heretics," New Scientist 170:34-7 (2001).</li> <li>Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entr mediator," Immunity 8:21-30 (1998).</li> <li>McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature 348:552 (1990).</li> <li>McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatologheath Professionals, Oral Presentation #1920 (November 16, 2005).</li> <li>Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," J. Immunol. 160:3-6 (1998).</li> <li>Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).</li> <li>Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260 (1999).</li> <li>Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med</li> </ul>		Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin a are ligands for herpesvirus entrimediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med</i>		Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
mediator," <i>Immunity</i> 8:21-30 (1998).  McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552 (1990).  McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i>		Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i>		Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).  Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i>		McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).  Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," <i>Cell</i> 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i>		population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology
receptor family," Cell 87:427-36 (1996).  Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260 (1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med.		Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
(1999).  Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med.		
		Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
84:817-25 (1988).		Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med. 84:817-25 (1988).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	M DISCLOSUDE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kB, and c-Jun NH <sub>2</sub> -terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," Blood 97:198-204 (2001).
Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include conv of this	

SUBSTITUTE FORM PTO-1449 U	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
·	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
	Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," <i>Eur. J. Immunol.</i> 18:1397-404 (1988).
	Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," <i>Scand. J. Immunol.</i> 31:213-24 (1990).
	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
	Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
	Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
	Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
	Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
	Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," <i>J. Exp. Med.</i> 197:297-302 (2003).
	Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 (1990).
	Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
	Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," <i>Science</i> 293:2111-4 (2001).
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," Gene 169:147-55 (1996).
	Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," Proc. Natl. Acad. Sci. USA 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EVAMINED leited station assistant Described Described Manager Station of the Stat	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
	Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
	Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
	Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," Science 277:818-21 (1997).
	Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," <i>J. Biol. Chem.</i> 276:6591-604 (2001).
3.34	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
	Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," <i>Proc. Natl. Acad. Sci. USA</i> 97:9156-61 (2000).
	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-19 (1997).
	Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
	Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).
	<u> </u>

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFIC	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INITODIAATI		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," Cell 66:1133-44 (1991).
Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
 Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," Virology 184:370-82 (1991).
Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," <i>J. Biol. Chem.</i> 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κB/lκB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," Science 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," <i>Arthritis Rheum</i> . 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," <i>Virology</i> 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODAMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(USE SEVERALS	silects if flecessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-52 (2001).
Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," J. Immur. 155:1994-2004 (1995).
Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated b ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
 Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).



Attorney Docket No. 50474/017002 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 10/626,914 Applicant Anan Chuntharapai et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 25, 2003 (Use several sheets if necessary) Group 1644 (37 C.F.R. § 1.98(b)) **IDS Filed** August 7, 2008

U.S. PATENT DOCUMENTS				
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
	3,773,919	Nov. 20, 1973	Boswell et al.	
	4,179,337	Dec. 18, 1979	Davis et al.	
	4,301,144	Nov. 17, 1981	lwashita et al.	
	4,496,689	Jan. 29, 1985	Mitra	
	4,640,835	Feb. 3, 1987	Shimizu et al.	
	4,670,417	Jun. 2, 1987	lwasaki et al.	
	4,791,192	Dec. 13, 1988	Nakagawa et al.	
	4,816,567	Mar. 28, 1989	Cabilly et al.	
	4,861,579	Aug. 29, 1989	Meyer et al.	
	5,182,196	Jan. 26, 1993	Allet et al.	
	5,262,309	Nov. 16, 1993	Nakamura et al.	
_	5,422,104	Jun. 6, 1995	Fiers et al.	
	5,428,130	Jun. 27, 1995	Capon et al.	
	5,486,463	Jan. 23, 1996	Lesslauer et al.	
	5,500,362	Mar. 19, 1996	Robinson et al.	
	5,519,119	May 21, 1996	Yamada et al.	
	5,540,926	Jul. 30, 1996	Aruffo et al.	
	5,587,457	Dec. 24, 1996	Rathjen et al.	
	5,595,721	Jan. 21, 1997	Kaminski et al.	
	5,610,279	Mar. 11, 1997	Brockhaus et al.	
	5,641,663	Jun. 24, 1997	Garvin et al.	
EXAMINER			DATE CONSIDERED	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
STATEMEN <sup>-</sup>	ON DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
5,652,353	Jul. 29, 1997	Fiers et al.	
5,677,180	Oct. 14, 1997	Robinson et al.	
5,721,108	Feb. 24, 1998	Robinson et al.	
5,736,137	Apr. 7, 1998	Anderson et al.	
5,776,456	Jul. 7, 1998	Anderson et al.	
5,808,029	Sep. 15, 1998	Brockhaus et al.	
5,821,337	Oct. 13, 1998	Carter et al.	
5,843,398	Dec. 1, 1998	Kaminski et al.	
5,843,439	Dec. 1, 1998	Anderson et al.	
5,849,898	Dec. 15, 1998	Seed et al.	
6,015,542	Jan. 18, 2000	Kaminski et al.	
6,090,365	Jul. 18, 2000	Kaminski et al.	
6,120,767	Sep. 19, 2000	Robinson et al.	
6,171,586	Jan. 9, 2001	Lam et al.	
6,171,787	Jan. 9, 2001	Wiley	
6,194,551	Feb. 27, 2001	Idusogie et al.	
6,224,866	May 1, 2001	Barbera-Guillem	
6,242,195	Jun. 5, 2001	Idusogie et al.	
6,287,537	Sep. 11, 2001	Kaminski et al.	
6,297,022	Oct. 2, 2001	McDonnell et al.	
6,297,367	Oct. 2, 2001	Tribouley	
6,306,393	Oct. 23, 2001	Goldenberg	
6,355,782	Mar. 12, 2002	Zonana et al.	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INITODAAATIO	NA DIGOLOGUE	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE  BY APPLICANT  Books if pagescaps)	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS				
	6,368,596	Apr. 9, 2002	Ghetie et al.		
	6,399,061	Jun. 4, 2002	Anderson et al.		
	6,403,770	Jun. 11, 2002	Yu et al.		
	6,410,391	Jun. 25, 2002	Zelsacher		
	6,440,694	Aug. 27, 2002	Bienkowski et al.		
	6,455,043	Sep. 24, 2002	Grillo-Lopez		
	6,475,986	Nov. 5, 2002	Aggarwal		
	6,475,987	Nov. 5, 2002	Shu		
	6,506,882	Jan. 14, 2003	Yu et al.		
	6,509,170	Jan. 21, 2003	Yu et al.		
	6,528,624	Mar. 4, 2003	Idusogie et al.		
	6,538,124	Mar. 25, 2003	Idusogie et al.		
	6,541,224	Apr. 1, 2003	Yu et al.		
-	6,551,795	Apr. 22, 2003	Rubenfield et al.		
	6,565,827	May 20, 2003	Kaminski et al.		
	6,652,852	Nov. 25, 2003	Robinson et al.		
	6,682,734	Jan. 27, 2004	Anderson et al.		
	6,869,605	Mar. 22, 2005	Browning et al.		
	6,875,846	Apr. 5, 2005	Rennert et al.		
	7,083,785	Aug. 1, 2006	Browning et al.		
	2001/0018041	Aug. 30, 2001	Hanna et al.		
	2002/0004587	Jan. 10, 2002	Miller et al.		
	2002/0006404	Jan. 17, 2002	Hanna et al.		

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
STATEMEN	ON DISCLOSURE IT BY APPLICANT sheets if necessary	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS				
2002/0009427	Jan. 24, 2002	Wolin et al.		
2002/0009444	Jan. 24, 2002	Grillo-Lopez		
2002/0012665	Jan. 31, 2002	Hanna		
2002/0037852	Mar. 28, 2002	Browning et al.		
2002/0041847	Apr. 11, 2002	Goldenberg		
2002/0058029	May 16, 2002	Hanna		
2002/0081296	Jun. 27, 2002	Theill et al.		
2002/0086018	Jul. 4, 2002	Theill et al.		
2002/0128488	Sep. 12, 2002	Yamakawa et al.		
2002/0136719	Sep. 26, 2002	Shenoy et al.		
2002/0165156	Nov. 7, 2002	Browning et al.		
2002/0172674	Nov. 21, 2002	Browning et al.		
2002/0197255	Dec. 26, 2002	Anderson et al.		
2002/0197256	Dec. 26, 2002	Grewal		
2003/0012783	Jan. 16, 2003	Kindsvogel		
2003/0021781	Jan. 30, 2003	Anderson et al.		
2003/0023038	Jan. 30, 2003	Rennert et al.		
2003/0026801	Feb. 6, 2003	Weiner et al.		
2003/0068664	Apr. 10, 2003	Albitar et al.		
2003/0082172	May 1, 2003	Anderson et al.		
2003/0082175	May 1, 2003	Schneider et al.		
2003/0092164	May 15, 2003	Gross et al.		
2003/0095963	May 22, 2003	Anderson et al.		

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	M DIOOL COURT	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS				
2003/0095967	May 22, 2003	MacKay et al.		
2003/0099990	May 29, 2003	Hsu		
2003/0103971	Jun. 5, 2003	Hariharan et al.		
2003/0133930	Jul. 17, 2003	Goldenberg et al.		
2003/0147885	Aug. 7, 2003	Anderson et al.		
2003/0157108	Aug. 21, 2003	Presta		
2003/0180292	Sep. 25, 2003	Hanna et al.		
2003/0185796	Oct. 2, 2003	Wolin et al.		
2003/0194743	Oct. 16, 2003	Beltzer et al.		
2003/0219433	Nov. 27, 2003	Hansen et al.		
2003/0219818	Nov. 27, 2003	Bohen et al.		
2004/0093621	May 13, 2004	Shitara et al.		
2005/0070689	Mar. 31, 2005	Dixit et al.		
2005/0095243	May 5, 2005	Chan et al.		
2005/0163775	Jul. 28, 2005	Chan et al.		
2006/0073146	Apr. 6, 2006	Ashkenazi et al.		
2006/0240517	Oct. 26, 2006	Ambrose et al.		
2006/0240519	Oct. 26, 2006	Ambrose et al.		
2006/0240520	Oct. 26, 2006	Ambrose et al.		
09/724,341	Nov. 28, 2000	Ashkenazi et al.		

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
NEODMATI	אין מוסטן סטוומר	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO .	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO .	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
-	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED
	- · · · · · · · · · · · · · · · · · · ·

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
WO 98/55620 A1	Dec. 10, 1998	WIPO		
WO 98/55621 A1	Dec. 10, 1998	WIPO		
WO 98/56418 A1	Dec. 17, 1998	WIPO		
WO 98/58964 A1	Dec. 30, 1998	WIPO		
WO 99/00518 A1	Jan. 7, 1999	WIPO		
WO 99/02653 A1	Jan. 21, 1999	WIPO		
WO 99/04001 A1	Jan. 28, 1999	WIPO		
WO 99/07738 A2	Feb. 18, 1999	WIPO		
WO 99/09165 A1	Feb. 25, 1999	WIPO		
WO 99/11791 A2	Mar. 11, 1999	WIPO		
WO 99/12964 A2	Mar. 18, 1999	WIPO .		
WO 99/12965 A2	Mar. 18, 1999	WIPO		
WO 99/19490 A1	Apr. 22, 1999	WIPO		
WO 99/22764 A1	May 14, 1999	WIPO		
WO 99/28462 A2	Jun. 10, 1999	WIPO		
WO 99/33980 A2	Jul. 8, 1999	WIPO		
WO 99/33988 A1	Jul. 8, 1999	WIPO		
WO 99/35170 A2	Jul. 15, 1999	WIPO		
WO 99/50416 A1	Oct. 7, 1999	WIPO		
WO 99/51642 A1	Oct. 14, 1999	WIPO		

EXAMINER	DATE CONSIDERED
<del></del>	

STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date Group	July 25, 2003
INFORMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
(MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449		Attorney Docket No.	50474/017002

	FOREIGN	PATENT OR PUBLIS	HED FOREIGN PATENT APPLICATION
	WO 00/09160 A1	Feb. 24, 2000	WIPO
	WO 00/20864 A1	Apr. 13, 2000	WIPO
-	WO 00/24811 A1	May 4, 2000	WIPO
	WO 00/26244 A2	May 11, 2000	WIPO
	WO 00/27428 A1	May 18, 2000	WIPO
	WO 00/27433 A1	May 18, 2000	WIPO
	WO 00/39295 A1	Jul. 6, 2000	WIPO
	WO 00/42072 A2	Jul. 20, 2000	-WIPO
	WO 00/43032 A2	Jul. 27, 2000	WIPO
	WO 00/44788 A1	Aug. 3, 2000	WIPO
	WO 00/45836 A1	Aug. 10, 2000	WIPO
	WO 00/50597 A2	Aug. 31, 2000	WIPO
	WO 00/50633 A1	Aug. 31, 2000	WIPO .
	WO 00/58362 A1	Oct. 5, 2000	WIPO
	WO 00/67795 A1	Nov. 16, 2000	WIPO ,
	WO 00/67796 A1	Nov. 16, 2000	WIPO
	WO 00/68378 A1	Nov. 16, 2000	WIPO
	WO 00/74718 A1	Dec. 14, 2000	WIPO
	WO 00/76542 A1	Dec. 21, 2000	WIPO
	WO 01/03734 A1	Jan. 18, 2001	WIPO

EXAM	MED	

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN	PATENT OR PUBLIS	SHED FOREIGN PATENT APPLICATION	
	WO 01/10460 A1 Feb. 15, 2001 WIPO			
,	WO 01/10461 A1	Feb. 15, 2001	WIPO	
	WO 01/10462 A1	Feb. 15, 2001	WIPO	
	WO 01/12812 A2	Feb. 22, 2001	WIPO	
	WO 01/13945 A1	Mar. 1, 2001	WIPO	
	WO 01/24811 A1	Apr. 12, 2001	WIPO	
	WO 01/25256 A2	Apr. 12, 2001	WIPO	
	WO 01/34194 A1	May 17, 2001	WIPO	
	WO 01/58949 A2	Aug. 16, 2001	WIPO	
	WO 01/60397 A1	Aug. 23, 2001	WIPO	
	WO 01/72333 A1	Oct. 4, 2001	WIPO	
	WO 01/74388 A1	Oct 11, 2001	WIPO	
	WO 01/77342 A1	Oct. 18, 2001	WIPO	
	WO 01/80844 A2	Nov. 1, 2001	WIPO	
	WO 01/96528 A2	Dec. 20, 2001	WIPO	
	WO 01/97858 A2	Dec. 27, 2001	WIPO	
	WO 02/02641 A1	Jan. 10, 2002	WIPO	
	WO 02/04021 A1	Jan. 17, 2002	WIPO	
	WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)	
	WO 02/16412 A2	Feb. 28, 2002	WIPO	

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
W	O 02/18620 A2	Mar. 7, 2002	WIPO	
W	O 02/24909 A2	Mar. 28, 2002	WIPO .	
W	O 02/34790 A1	May 2, 2002	WIPO	
W	O 02/38766 A2	May 16, 2002	WIPO	
W	O 02/060485 A2	Aug. 8, 2002	WIPO	
W	O 02/060955 A2	Aug. 8, 2002	WIPO	
W	O 02/079255 A1	Oct. 10, 2002	WIPO	
W	O 02/092620 A2	Nov. 21, 2002	WIPO	
W	O 02/094192 A2	Nov. 28, 2002	WIPO	
W	O 02/094852 A2	Nov. 28, 2002	WIPO	
W	O 02/096948 A2	Dec. 5, 2002	WIPO	
W	O 02/102312 A2	Dec. 27, 2002	WIPO	
W	O 03/002607 A1	Jan. 9, 2003	WIPO	
W	O 03/014294 A2	Feb. 20, 2003	WIPO	
W	O 03/024991 A2	Mar. 27, 2003	WIPO	
W	O 03/033658 A2	Apr. 24, 2003	WIPO	
W	O 03/035846 A2	May 1, 2003	WIPO	
W	O 03/045421 A1	Jun. 5, 2003	WIPO	
W	O 03/049694 A2	Jun. 19, 2003	WIPO	
W	O 03/055979 A2	Jul. 10, 2003	WIPO	

EXAMINER	DATE CONSIDERED
EVALUED 1.70.1.70.10.	if a time of a second depth of the second dept

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INTORMATION DICCLOCURE		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 03	3/061694 A1	Jul. 31, 2003	WIPO	
WO 03	3/068821 A2	Aug. 21, 2003	WIPO	
WO 20	004/011611 A2	Feb. 5, 2004	WIPO	
WO 20	004/032828 A2	Apr. 22, 2004	WIPO	]
WO 20	004/035607 A2	Арг. 29, 2004	WIPO	
WO 20	004/056312 A2	Jul. 8, 2004	WIPO	
WO 20	004/081043 A2	Sep. 23, 2004	WIPO	]
WO 20	005/000351 A2	Jan. 6, 2005	WIPO	
WO 20	005/005462 A2	Jan. 20, 2005	WIPO	
WO 20	006/052493 A1	May 18, 2006	WIPO	
WO 20	006/068867 A1	May 29, 2006	WIPO	
WO 20	006/073941 A2	Jul. 13, 2006	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER		DATE CONSIDERED	
	EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	A CONTRACT OF THE PROPERTY OF
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
	Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
	Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
	Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
	Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
	Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
	Baldwin, "The NF-κB and IkB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
	Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
	Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
	Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
	Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
<u> </u>	Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
	Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
	Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
	Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," Cell 72:847-56 (1993).
<del></del>	Callard et al., "CD40 ligand and its role in X-linked hyper-IgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)  Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest.
54:26-31 (1986).
Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," <i>Nature</i> 283:666-8 (1980).
Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ," <i>Eur. J. Immunol.</i> 17:689-93 (1987).
Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-кВ and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citati form with the next communication to applicant.	on if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science 261:1328-30 (1993).
	Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
	Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," Rheumatology 40:205-11 (2001).
-	Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
	Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
	Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
	Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
	Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
	Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
	Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
	GenBank accession number AF046888
	GenBank accession number AF136293
	GenBank accession number AK008142
	GenBank accession number Al250289, XP002206618
	GenBank accession number Z99716.4, XP002206619
	Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
	Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citat form with the next communication to applicant.	ion if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. §· 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," Cell 73:447-56 (1993).
Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," Mol. Cell. Biol. 11:3020-6 (1991).
Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," <i>Science</i> 273:1864-7 (1996).
Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," <i>Genome Res.</i> 10:237-43 (2000).
Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this	

(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008
(Use several sneets if necessary)		Group	1644
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-7 (1993).
Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," J. Biol. Chem. 264:14927-34 (1989).
Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," <i>Science</i> 253:1278-80 (1991).
Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Mol. Immunol.</i> 28:1027-37 (1991).
Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).
International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include conv of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum.</i> 39:797-809 (1996).
Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).
Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," <i>Leuk. Res.</i> 11:1119-25 (1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	· ·	DATE CONSIDERED
EVAMINED: Initial attation considered	Drow line through citation	if not in conformance and not considered. Include conv of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	M DICCI CCUDE	Applicant	Anan Chuntharapai et al.
STATEMENT	ON DISCLOSURE  BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
Kwon et al., "Single amino acid substitutions of α <sub>1</sub> -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," Curr. Opin. Immunol. 11:340-5 (1999).
Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
Lane et al., "B cell function in mice transgenic for mCTLA-Hγ1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum</i> . 46:2673-7 (2002).
Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," <i>Arthritis Rheum.</i> 44:S370, Abstract No. 1905 (2001).
Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHO	PR, TITLE, DATE, PLACE OF PUBLICATION)			
	Lentz et al., "Bcmd decreases the life span of B-(1998).	2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7			
	Lesley et al., "Reduced competitiveness of autoa Immunity 20:441-53 (2004).	antigen-engaged B cells due to increased dependence on BAFF,			
	Levine and Pestronk, "IgM antibody-related poly Neurology 52:1701-4 (1999).	neuropathies: B-cell depletion chemotherapy using rituximab,"			
	Lewis et al., "Cloning and expression of cDNAs demonstrate one receptor is species specific," P	for two distinct murine tumor necrosis factor receptors Proc. Natl. Acad. Sci. USA 88:2830-4 (1991).			
	Linsley et al., "Immunosuppression in vivo by a s 257:792-5 (1992).	soluble form of the CTLA-4 T cell activation molecule," Science			
	Locksley et al., "The TNF and TNF receptor sup (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501			
	Loetscher et al., "Molecular cloning and express 61:351-9 (1990).	ion of the human 55 kd tumor necrosis factor receptor," Cell			
	Lotz et al., "The nerve growth factor/tumor necro	sis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).			
	MacFarlane et al., "Identification and molecular of Biol. Chem. 272:25417-20 (1997).	cloning of two novel receptors for the cytotoxic ligand TRAIL," J.			
	Mackay and Browning, "BAFF: a fundamental su	uvival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002).			
	Mackay et al., "Mice transgenic for BAFF develo J. Exp. Med. 190:1697-710 (1999).	p lymphocytic disorders along with autoimmune manifestations,"			
	Mackay et al., "BAFF and APRIL: a tutorial on B	cell survival," Annu. Rev. Immunol. 21:231-64 (2003).			
	MacLennan, "Germinal centers," Annu. Rev. Imr.	nunol. 12:117-39 (1994).			
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Int. Immunol.</i> 10:1693-702 (1998).				
-	Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumat <i>Immunol. Rev.</i> 144:195-223 (1995).				
	Mallett et al., "Characterization of the MRC OX40 related to nerve growth factor receptor," EMBO	D antigen of activated CD4 positive T lymphocytes – a molecule J. 9:1063-8 (1990).			
	Mandala et al., "Alteration of lymphocyte trafficking 296:346-9 (2002).	ng by sphingosine-1-phosphate receptor agonists," Science			
EXAMINER		DATE CONSIDERED			

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	N DIGGLOGUE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB," <i>Curr. Biol.</i> 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-κB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med. 84:817-25 (1988).

EXAMINER		DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH₂-terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
 Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," Blood 97:198-204 (2001).
Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," J. Biol. Chem. 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," Eur. J. Immunol. 18:1397-404 (1988).
Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immunol. 31:213-24 (1990).
Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," <i>J. Exp. Med.</i> 197:297-302 (2003).
Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," <i>Cell</i> 61:361-70 (1990).
Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," Science 293:2111-4 (2001).
Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 169:147-55 (1996).
Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," <i>Proc. Natl. Acad. Sci. USA</i> 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include conv of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
 Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative premRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," <i>Science</i> 277:818-21 (1997).
Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," <i>J. Biol. Chem.</i> 276:6591-604 (2001).
Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," J. Leukocyte Biol. 65:680-3 (1999).
 Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," Proc. Natl. Acad. Sci. USA 97:9156-61 (2000).
Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-19 (1997).
 Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," Cell 66:1133-44 (1991).
Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," Virology 160:20-30 (1987).
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," J. Biol. Chem. 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	NA DICOLOCUDE	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE  T BY APPLICANT  hoote if possesses	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κB/lκB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," Science 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," Ther. Immunol. 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," <i>Arthritis Rheum</i> . 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," Virology 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED	
EVAMINED: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include compared this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
STATEMEN	T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
	Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
	Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
	Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-52 (2001).
	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
• • •	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
	Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
	Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," J. Immunol. 166:6-10 (2001).
	Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EXAMINER	
----------	--

AUG 1 1 2008 PAR MARINE

SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Attorney Docket No.

50474/017002

Serial No. Applicant 10/626,914

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Filing Date

July 25, 2003

Anan Chuntharapai et al.

(Use several sheets if necessary)

Group

1644

(37 C.F.R. § 1.98(b))

**IDS Filed** 

August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	lwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	Iwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
-	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
	5,540,926	Jul. 30, 1996	Aruffo et al.
	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER			DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATIC	ON DIGGLOGUES	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS				
5,652,353	Jul. 29, 1997	Fiers et al.		
5,677,180	Oct. 14, 1997	Robinson et al.		
5,721,108	Feb. 24, 1998	Robinson et al.		
5,736,137	Apr. 7, 1998	Anderson et al.		
5,776,456	Jul. 7, 1998	Anderson et al.		
5,808,029	Sep. 15, 1998	Brockhaus et al.		
5,821,337	Oct. 13, 1998	Carter et al.		
5,843,398	Dec. 1, 1998	Kaminski et al.		
5,843,439	Dec. 1, 1998	Anderson et al.		
5,849,898	Dec. 15, 1998	Seed et al.		
6,015,542	Jan. 18, 2000	Kaminski et al.		
6,090,365	Jul. 18, 2000	Kaminski et al.		
6,120,767	Sep. 19, 2000	Robinson et al.		
6,171,586	Jan. 9, 2001	Lam et al.		
6,171,787	Jan. 9, 2001	Wiley		
6,194,551	Feb. 27, 2001	Idusogie et al.		
6,224,866	May 1, 2001	Barbera-Guillem		
6,242,195	Jun. 5, 2001	Idusogie et al.		
6,287,537	Sep. 11, 2001	Kaminski et al.		
6,297,022	Oct. 2, 2001	McDonnell et al.		
6,297,367	Oct. 2, 2001	Tribouley		
6,306,393	Oct. 23, 2001	Goldenberg		
6,355,782	Mar. 12, 2002	Zonana et al.		

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
,	NA DIGO I GOLIDE	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE TBY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS				
 6,368,596	Apr. 9, 2002	Ghetie et al.		
6,399,061	Jun. 4, 2002	Anderson et al.		
6,403,770	Jun. 11, 2002	Yu et al.		
6,410,391	Jun. 25, 2002	Zelsacher		
6,440,694	Aug. 27, 2002	Bienkowski et al.		
6,455,043	Sep. 24, 2002	Grillo-Lopez		
6,475,986	Nov. 5, 2002	Aggarwal		
6,475,987	Nov. 5, 2002	Shu		
6,506,882	Jan. 14, 2003	Yu et al.		
6,509,170	Jan. 21, 2003	Yu et al.		
6,528,624	Mar. 4, 2003	Idusogie et al.		
6,538,124	Mar. 25, 2003	Idusogie et al.		
6,541,224	Apr. 1, 2003	Yu et al.		
6,551,795	Apr. 22, 2003	Rubenfield et al.		
6,565,827	May 20, 2003	Kaminski et al.		
6,652,852	Nov. 25, 2003	Robinson et al.		
6,682,734	Jan. 27, 2004	Anderson et al.		
6,869,605	Mar. 22, 2005	Browning et al.		
6,875,846	Apr. 5, 2005	Rennert et al.		
7,083,785	Aug. 1, 2006	Browning et al.		
2001/0018041	Aug. 30, 2001	Hanna et al.		
2002/0004587	Jan. 10, 2002	Miller et al.		
2002/0006404	Jan. 17, 2002	Hanna et al.		

EXAM	INER
------	------

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON BIGGLOCUES	Applicant	Anan Chuntharapai et al.
STATEMEN	ON DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
2002/0009427	Jan. 24, 2002	Wolin et al.
2002/0009444	Jan. 24, 2002	Grillo-Lopez
2002/0012665	Jan. 31, 2002	Hanna
2002/0037852	Mar. 28, 2002	Browning et al.
2002/0041847	Apr. 11, 2002	Goldenberg
2002/0058029	May 16, 2002	Hanna
2002/0081296	Jun. 27, 2002	Theill et al.
2002/0086018	Jul. 4, 2002	Theill et al.
2002/0128488	Sep. 12, 2002	Yamakawa et al.
2002/0136719	Sep. 26, 2002	Shenoy et al.
2002/0165156	Nov. 7, 2002	Browning et al.
2002/0172674	Nov. 21, 2002	Browning et al.
2002/0197255	Dec. 26, 2002	Anderson et al.
2002/0197256	Dec. 26, 2002	Grewal
2003/0012783	Jan. 16, 2003	Kindsvogel
2003/0021781	Jan. 30, 2003	Anderson et al.
2003/0023038	Jan. 30, 2003	Rennert et al.
2003/0026801	Feb. 6, 2003	Weiner et al.
2003/0068664	Apr. 10, 2003	Albitar et al.
2003/0082172	May 1, 2003	Anderson et al.
2003/0082175	May 1, 2003	Schneider et al.
2003/0092164	May 15, 2003	Gross et al.
2003/0095963	May 22, 2003	Anderson et al.

EXAM	IINER
------	-------

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT C	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS			
2003/009	95967	May 22, 2003	MacKay et al.	
2003/009	9990	May 29, 2003	Hsu	
2003/010	03971	Jun. 5, 2003	Hariharan et al.	
2003/013	33930	Jul. 17, 2003	Goldenberg et al.	
2003/014	17885	Aug. 7, 2003	Anderson et al.	
2003/015	57108	Aug. 21, 2003	Presta	
2003/018	30292	Sep. 25, 2003	Hanna et al.	
2003/018	35796	Oct. 2, 2003	Wolin et al.	
2003/019	94743	Oct. 16, 2003	Beltzer et al.	
2003/021	19433	Nov. 27, 2003	Hansen et al.	
2003/021	19818	Nov. 27, 2003	Bohen et al.	
2004/009	93621	May 13, 2004	Shitara et al.	
2005/007	70689	Mar. 31, 2005	Dixit et al.	
2005/009	95243	May 5, 2005	Chan et al.	
2005/016	3775	Jul. 28, 2005	Chan et al.	
2006/007	73146	Apr. 6, 2006	Ashkenazi et al.	
2006/024	10517	Oct. 26, 2006	Ambrose et al.	
2006/024	10519	Oct. 26, 2006	Ambrose et al.	
2006/024	10520	Oct. 26, 2006	Ambrose et al.	
09/724,3	41	Nov. 28, 2000	Ashkenazi et al.	

EXAMINER	DATE CONSIDERED

	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
NEODAAT.	ON DIGG! OCUDE	Applicant	Anan Chuntharapai et al.
STATEMEN	ON DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXA	MIN	<b>IER</b>
-----	-----	------------

DATE CONSIDERED

(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008
(Use several sheets if necessary)		Group	1644
STATEMENT	DN DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
, , , , , , , , , , , , , , , , , , ,	NU DIONI 001155	Applicant	Anan Chuntharapai et al.
(MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449		Attorney Docket No.	50474/017002

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO 98/55620 A1	Dec. 10, 1998	WIPO
	WO 98/55621 A1	Dec. 10, 1998	WIPO
	WO 98/56418 A1	Dec. 17, 1998	WIPO
	WO 98/58964 A1	Dec. 30, 1998	WIPO
	WO 99/00518 A1	Jan. 7, 1999	WIPO
	WO 99/02653 A1	Jan. 21, 1999	WIPO
	WO 99/04001 A1	Jan. 28, 1999	WIPO
	WO 99/07738 A2	Feb. 18, 1999	WIPO
	WO 99/09165 A1	Feb. 25, 1999	WIPO
	WO 99/11791 A2	Mar. 11, 1999	WIPO
	WO 99/12964 A2	Mar. 18, 1999	WIPO
	WO 99/12965 A2	Mar. 18, 1999	WIPO .
	WO 99/19490 A1	Арг. 22, 1999	WIPO
	WO 99/22764 A1	May 14, 1999	WIPO
	WO 99/28462 A2	Jun. 10, 1999	WIPO
	WO 99/33980 A2	Jul. 8, 1999	WIPO
	WO 99/33988 A1	Jul. 8, 1999	WIPO
	WO 99/35170 A2	Jul. 15, 1999	WIPO
	WO 99/50416 A1	Oct. 7, 1999	WIPO
	WO 99/51642 A1	Oct. 14, 1999	WIPO

EXAMINER	DATE CONSIDERED
	· · · · · · · · · · · · · · · · · · ·

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Filing Date	Anan Chuntharapai et al.  July 25, 2003
(Use several sheets if necessary)	Group	1644
(37 C.F.R. § 1.98(b))	IDS Filed	August 7, 2008

	FOREIGN P	ATENT OR PUBLISH	ED FOREIGN PATENT APPLICATION
WO 00	/09160 A1	Feb. 24, 2000	WIPO
WO 00	/20864 A1	Apr. 13, 2000	WIPO
- WO 00	/24811 A1	May 4, 2000	WIPO
WO 00	/26244 A2	May 11, 2000	WIPO
WO 00	/27428 A1	May 18, 2000	WIPO
WO 00	/27433 A1	May 18, 2000	WIPO
WO 00	/39295 A1	Jul. 6, 2000	WIPO
WO 00	/42072 A2	Jul. 20, 2000	·WIPO
WO 00	/43032 A2	Jul. 27, 2000	WIPO
WO 00	/44788 A1	Aug. 3, 2000	WIPO
WO 00	/45836 A1	Aug. 10, 2000	WIPO
WO 00	/50597 A2	Aug. 31, 2000	WIPO
WO 00	/50633 A1	Aug. 31, 2000	WIPO
WO 00	/58362 A1	Oct. 5, 2000	WIPO
WO 00	/67795 A1	Nov. 16, 2000	WIPO
WO 00	/67796 A1	Nov. 16, 2000	WIPO
WO 00	)/68378 A1	Nov. 16, 2000	WIPO
WO 00	/74718 A1	Dec. 14, 2000	WIPO
WO 00	/76542 A1	Dec. 21, 2000	WIPO .
WO 01	/03734 A1	Jan. 18, 2001	WIPO

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 U.	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) P.	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
NISODIME	0,00,00,00	Applicant	Anan Chuntharapai et al.
INFORMATION I STATEMENT BY	Y APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 01/10460 A1	Feb. 15, 2001	WIPO	
WO 01/10461 A1	Feb. 15, 2001	WIPO	
WO 01/10462 A1	Feb. 15, 2001	WIPO	
WO 01/12812 A2	Feb. 22, 2001	WIPO	
WO 01/13945 A1	Mar. 1, 2001	WIPO	
WO 01/24811 A1	Apr. 12, 2001	WIPO	
WO 01/25256 A2	Apr. 12, 2001	WIPO	
WO 01/34194 A1	May 17, 2001	WIPO	
WO 01/58949 A2	Aug. 16, 2001	WIPO	
WO 01/60397 A1	Aug. 23, 2001	WIPO	
WO 01/72333 A1	Oct. 4, 2001	WIPO	
WO 01/74388 A1	Oct 11, 2001	WIPO	
WO 01/77342 A1	Oct. 18, 2001	WIPO	
WO 01/80844 A2	Nov. 1, 2001	WIPO	
WO 01/96528 A2	Dec. 20, 2001	WIPO	
WO 01/97858 A2	Dec. 27, 2001	WIPO	
WO 02/02641 A1	Jan. 10, 2002	WIPO	
WO 02/04021 A1	Jan. 17, 2002	WIPO	
WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)	
WO 02/16412 A2	Feb. 28, 2002	WIPO	

EXAMINER	DATE CONSIDERED
I	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date Group	July 25, 2003
STATEMEN	T BY APPLICANT	Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

FOREIGN	PATENT OR PUBLIS	HED FOREIGN PATENT APPLICATION	
WO 02/18620 A2	Mar. 7, 2002	WIPO	
WO 02/24909 A2	Mar. 28, 2002	WIPO	
WO 02/34790 A1	May 2, 2002	WIPO	
WO 02/38766 A2	May 16, 2002	WIPO	٦
WO 02/060485 A2	Aug. 8, 2002	WIPO	$\exists$
WO 02/060955 A2	Aug. 8, 2002	WIPO	
WO 02/079255 A1	Oct. 10, 2002	WIPO	
 WO 02/092620 A2	Nov. 21, 2002	WIPO	
WO 02/094192 A2	Nov. 28, 2002	WIPO	
WO 02/094852 A2	Nov. 28, 2002	WIPO	
WO 02/096948 A2	Dec. 5, 2002	WIPO	
WO 02/102312 A2	Dec. 27, 2002	WIPO	
WO 03/002607 A1	Jan. 9, 2003	WIPO	
WO 03/014294 A2	Feb. 20, 2003	WIPO	
WO 03/024991 A2	Mar. 27, 2003	WIPO	
WO 03/033658 A2	Apr. 24, 2003	WIPO	٦
WO 03/035846 A2	May 1, 2003	WIPO	╗
WO 03/045421 A1	Jun. 5, 2003	WIPO	$\exists$
WO 03/049694 A2	Jun. 19, 2003	WIPO	
WO 03/055979 A2	Jul. 10, 2003	WIPO	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Applicant	Anan Chuntharapai et al.
STATEMEN'	ON DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
woo	3/061694 A1	Jul. 31, 2003	WIPO	
WO 0	3/068821 A2	Aug. 21, 2003	WIPO	
WO 2	004/011611 A2	Feb. 5, 2004	WIPO	
WO 2	004/032828 A2	Apr. 22, 2004	WIPO	**
WO 2	004/035607 A2	Apr. 29, 2004	WIPO	
WO 2	004/056312 A2	Jul. 8, 2004	WIPO	
WO 2	004/081043 A2	Sep. 23, 2004	WIPO	
WO 2	005/000351 A2	Jan. 6, 2005	WIPO	
WO 2	005/005462 A2	Jan. 20, 2005	WIPO	
WO 2	006/052493 A1	May 18, 2006	WIPO	
WO 2	006/068867 A1	May 29, 2006	WIPO	
WO 2	006/073941 A2	Jul. 13, 2006	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
 Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
	Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
	Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome," Cell 72:291-300 (1993).
,	Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
	Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," Proc. Natl. Acad. Sci. USA 88:10535-9 (1991).
	Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
	Baldwin, "The NF-κB and IκB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
	Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
	Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
	Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
	Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
-	Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
	Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
	Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
	Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
	Callard et al., "CD40 ligand and its role in X-linked hyper-IgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31 (1986).
	Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
	Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
-	Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
	Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
	Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666-8 (1980).
	Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," Blood 101:1045-52 (2003).
	Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
	Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
	Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ," Eur. J. Immunol. 17:689-93 (1987).
	Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
	Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
	De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
	Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
	Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science 261:1328-30 (1993).
Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," <i>Rheumatology</i> 40:205-11 (2001).
Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
 Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
GenBank accession number AF046888
GenBank accession number AF136293
GenBank accession number AK008142
 GenBank accession number Al250289, XP002206618
GenBank accession number Z99716.4, XP002206619
Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this	

	449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR THE PART OF SURFICATION)
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," <i>Cell</i> 73:447-56 (1993).
	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
	Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
	Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
	Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
	Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
	Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
	Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
	Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," <i>Science</i> 273:1864-7 (1996).
	Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
	Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
	Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
	Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," <i>Genome Res.</i> 10:237-43 (2000).
	Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).
-	

EXAMINER		DATE CONSIDERED
	EYAMINED: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include convert this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-7 (1993).
 Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," <i>J. Biol. Chem.</i> 264:14927-34 (1989).
Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).
Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).
 Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <i>J. Immunol.</i> 164:4178-84 (2000).
International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
 International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citatio	n if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADER	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum</i> . 39:797-809 (1996).
Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-кB2," <i>Immunity</i> 10:515-24 (2002).
Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," <i>Leuk. Res.</i> 11:1119-25 (1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citatio form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	· · · · · · · · · · · · · · · · · · ·
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
	Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
	Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
	Kwon et al., "Single amino acid substitutions of α <sub>1</sub> -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
	Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," Curr. Opin. Immunol. 11:340-5 (1999).
	Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
-	Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
	Lane et al., "B cell function in mice transgenic for mCTLA-Hy1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
	Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum.</i> 46:2673-7 (2002).
	Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," Arthritis Rheum. 44:S370, Abstract No. 1905 (2001).
	Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
	Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
	Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
	Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	MODIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

EXAMINER		DATE CONSIDERED	
	Mandala et al., "Alteration of lymphocyte trafficki 296:346-9 (2002).	ng by sphingosine-1-phosphate receptor agonists," Science	
	Mallett et al., "Characterization of the MRC OX40 related to nerve growth factor receptor," <i>EMBO</i> .	0 antigen of activated CD4 positive T lymphocytes – a molecule J. 9:1063-8 (1990).	
	Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease," <i>Immunol. Rev.</i> 144:195-223 (1995).		
	MacLennan, "Germinal centers," <i>Annu. Rev. Immunol.</i> 12:117-39 (1994).  Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Int. Immunol.</i> 10:1693-702 (1998).		
	Mackay et al., "BAFF and APRIL: a tutorial on B	cell survival," Annu. Rev. Immunol. 21:231-64 (2003).	
	Mackay et al., "Mice transgenic for BAFF develor J. Exp. Med. 190:1697-710 (1999).	p lymphocytic disorders along with autoimmune manifestations,	
	Mackay and Browning, "BAFF: a fundamental su	rivival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002)	
	MacFarlane et al., "Identification and molecular of Biol. Chem. 272:25417-20 (1997).	cloning of two novel receptors for the cytotoxic ligand TRAIL," J.	
	Lotz et al., "The nerve growth factor/tumor necro	sis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).	
	Loetscher et al., "Molecular cloning and expressi 61:351-9 (1990).	ion of the human 55 kd tumor necrosis factor receptor," Cell	
	Locksley et al., "The TNF and TNF receptor super (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501	
	Linsley et al., "Immunosuppression in vivo by a s 257:792-5 (1992).	coluble form of the CTLA-4 T cell activation molecule," Science	
	Lewis et al., "Cloning and expression of cDNAs f demonstrate one receptor is species specific," Proceedings of the control of	for two distinct murine tumor necrosis factor receptors roc. Natl. Acad. Sci. USA 88:2830-4 (1991).	
	Levine and Pestronk, "IgM antibody-related polyi Neurology 52:1701-4 (1999).	neuropathies: B-cell depletion chemotherapy using rituximab,"	
	Lesley et al., "Reduced competitiveness of autoa Immunity 20:441-53 (2004).	intigen-engaged B cells due to increased dependence on BAFF	
	Lentz et al., "Bcmd decreases the life span of B-2 (1998).	2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7	
	OTHER DOCUMENTS (INCLUDING AUTHO	.,,	

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-кВ," <i>Curr. Biol.</i> 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-κB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med. 84:817-25 (1988).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	0-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH₂-terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
	Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
	Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
	Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," <i>Blood</i> 97:198-204 (2001).
	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
	Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
	Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
	Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
·	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
	Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
	Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
	Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
	Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
	Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
	Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	n if not in conformance and not considered. Include copy of this

1	J.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
(Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," Nature 396:699-703 (1998).
Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence or regulation by selective endothelial and homotypic adhesion," Eur. J. Immunol. 18:1397-404 (1988).
Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immunol. 31:213-24 (1990).
Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 1987).
Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 1987).
Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 33:435-45 (1994).
Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family nember APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in points," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," J. Exp. Med. 197:297- 802 (2003).
Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 1990).
Schein, "Production of soluble recombinant proteins in bacteria," <i>Bio-Technol.</i> 7:1141-9 (1989).
Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," Science 293:2111-4 (2001).
Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 69:147-55 (1996).
Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, ymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," <i>Proc. Natl. Acad. Sci. USA</i> 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
(Use several s	heets if necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
	Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
	Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
	Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," <i>Science</i> 277:818-21 (1997).
	Shields et al., "High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgG1 variants with improved binding to the FcyR*," J. Biol. Chem. 276:6591-604 (2001).
	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
·	Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," Proc. Natl. Acad. Sci. USA 97:9156-61 (2000).
	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-19 (1997).
	Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," <i>Science</i> 248:1019-23 (1990).
	Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	DIFIED) PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
N/500147101/01/01/07		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	July 25, 2003	
	Group	1644	
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," Cell 66:1133-44 (1991).
Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," <i>J. Biol. Chem.</i> 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	July 25, 2003	
	Group	1644	
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κB/lkB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," <i>Science</i> 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," <i>Arthritis Rheum</i> . 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," Virology 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
11150111151011510115		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	July 25, 2003	
	Group	1644	
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

<del></del>	
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
	Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
	Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
	Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," Curr. Biol. 11:1547-52 (2001).
	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
	Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
,	Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
<u> </u>	Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EXA	B #1	NEC	,
	AVII.	NEH	٤

AUG 11 2008 SHATE TRADEME Sheet <u>1</u> of <u>26</u> Attorney Docket No. 50474/017002 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 10/626,914 Applicant Anan Chuntharapai et al. INFORMATION DISCLOSURE Filing Date July 25, 2003 STATEMENT BY APPLICANT (Use several sheets if necessary) Group 1644 (37 C.F.R. § 1.98(b)) **IDS Filed** August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Document Publication Patentee or Applicant Date		Patentee or Applicant	
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	lwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	lwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
-	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
-	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
	5,540,926	Jul. 30, 1996	Aruffo et al.
	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER			DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
5,652,353	Jul. 29, 1997	Fiers et al.
5,677,180	Oct. 14, 1997	Robinson et al.
5,721,108	Feb. 24, 1998	Robinson et al.
5,736,137	Apr. 7, 1998	Anderson et al.
5,776,456	Jul. 7, 1998	Anderson et al.
5,808,029	Sep. 15, 1998	Brockhaus et al.
5,821,337	Oct. 13, 1998	Carter et al.
5,843,398	Dec. 1, 1998	Kaminski et al.
5,843,439	Dec. 1, 1998	Anderson et al.
5,849,898	Dec. 15, 1998	Seed et al.
6,015,542	Jan. 18, 2000	Kaminski et al.
6,090,365	Jul. 18, 2000	Kaminski et al.
6,120,767	Sep. 19, 2000	Robinson et al.
6,171,586	Jan. 9, 2001	Lam et al.
6,171,787	Jan. 9, 2001	Wiley
6,194,551	Feb. 27, 2001	Idusogie et al.
6,224,866	May 1, 2001	Barbera-Guillem
6,242,195	Jun. 5, 2001	Idusogie et al.
6,287,537	Sep. 11, 2001	Kaminski et al.
6,297,022	Oct. 2, 2001	McDonnell et al.
6,297,367	Oct. 2, 2001	Tribouley
6,306,393	Oct. 23, 2001	Goldenberg
6,355,782	Mar. 12, 2002	Zonana et al.

EXAMINER	DATE CONSIDERED
EVAMINED: Initial citation considered. Drawling through citation	if not in conformance and not considered. Include come of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
***************************************		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
6,368,596	Apr. 9, 2002	Ghetie et al.
6,399,061	Jun. 4, 2002	Anderson et al.
6,403,770	Jun. 11, 2002	Yu et al.
6,410,391	Jun. 25, 2002	Zelsacher
6,440,694	Aug. 27, 2002	Bienkowski et al.
6,455,043	Sep. 24, 2002	Grillo-Lopez
6,475,986	Nov. 5, 2002	Aggarwal
6,475,987	Nov. 5, 2002	Shu
6,506,882	Jan. 14, 2003	Yu et al.
6,509,170	Jan. 21, 2003	Yu et al.
6,528,624	Mar. 4, 2003	Idusogie et al.
6,538,124	Mar. 25, 2003	Idusogie et al.
6,541,224	Apr. 1, 2003	Yu et al.
6,551,795	Apr. 22, 2003	Rubenfield et al.
6,565,827	May 20, 2003	Kaminski et al.
6,652,852	Nov. 25, 2003	Robinson et al.
 6,682,734	Jan. 27, 2004	Anderson et al.
6,869,605	Mar. 22, 2005	Browning et al.
6,875,846	Apr. 5, 2005	Rennert et al.
7,083,785	Aug. 1, 2006	Browning et al.
2001/0018041	Aug. 30, 2001	Hanna et al.
2002/0004587	Jan. 10, 2002	Miller et al.
2002/0006404	Jan. 17, 2002	Hanna et al.

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
2002/0009427	Jan. 24, 2002	Wolin et al.
2002/0009444	Jan. 24, 2002	Grillo-Lopez
2002/0012665	Jan. 31, 2002	Hanna
2002/0037852	Mar. 28, 2002	Browning et al.
2002/0041847	Apr. 11, 2002	Goldenberg
2002/0058029	May 16, 2002	Hanna
2002/0081296	Jun. 27, 2002	Theill et al.
2002/0086018	Jul. 4, 2002	Theill et al.
2002/0128488	Sep. 12, 2002	Yamakawa et al.
2002/0136719	Sep. 26, 2002	Shenoy et al.
2002/0165156	Nov. 7, 2002	Browning et al.
2002/0172674	Nov. 21, 2002	Browning et al.
2002/0197255	Dec. 26, 2002	Anderson et al.
2002/0197256	Dec. 26, 2002	Grewal
2003/0012783	Jan. 16, 2003	Kindsvogel
2003/0021781	Jan. 30, 2003	Anderson et al.
2003/0023038	Jan. 30, 2003	Rennert et al.
2003/0026801	Feb. 6, 2003	Weiner et al.
2003/0068664	Apr. 10, 2003	Albitar et al.
2003/0082172	May 1, 2003	Anderson et al.
2003/0082175	May 1, 2003	Schneider et al.
2003/0092164	May 15, 2003	Gross et al.
2003/0095963	May 22, 2003	Anderson et al.

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50474/017002
		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sr	neets if necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	U.S. PATENT DOCUMENTS	
2003/0095967	May 22, 2003	MacKay et al.
2003/0099990	May 29, 2003	Hsu
2003/0103971	Jun. 5, 2003	Hariharan et al.
2003/0133930	Jul. 17, 2003	Goldenberg et al.
2003/0147885	Aug. 7, 2003	Anderson et al.
2003/0157108	Aug. 21, 2003	Presta
2003/0180292	Sep. 25, 2003	Hanna et al.
2003/0185796	Oct. 2, 2003	Wolin et al.
2003/0194743	Oct. 16, 2003	Beltzer et al.
2003/0219433	Nov. 27, 2003	Hansen et al.
2003/0219818	Nov. 27, 2003	Bohen et al.
2004/0093621	May 13, 2004	Shitara et al.
2005/0070689	Mar. 31, 2005	Dixit et al.
2005/0095243	May 5, 2005	Chan et al.
2005/0163775	Jul. 28, 2005	Chan et al.
2006/0073146	Apr. 6, 2006	Ashkenazi et al.
2006/0240517	Oct. 26, 2006	Ambrose et al.
2006/0240519	Oct. 26, 2006	Ambrose et al.
2006/0240520	Oct. 26, 2006	Ambrose et al.
09/724,341	Nov. 28, 2000	Ashkenazi et al.

EXAMINER	DATE CONSIDERED

(MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50474/017002
		Serial No.	10/626,914
NEODIATIO	N DIOOLOGUET	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Ose several sn	eets if necessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN	PATENT OR PUBLIS	HED FOREIGN PATENT APPLICATION	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
<del></del>	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	_
	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED
<del>-</del>	L <del>aure</del> .

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE		Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
INCODAGATI	ON DICCLOCUPE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Ose several s	silects if flecessary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

. FOREIGN F	PATENT OR PUBLISH	IED FOREIGN PATENT APPLICATION
WO 98/55620 A1	Dec. 10, 1998	WIPO
WO 98/55621 A1	Dec. 10, 1998	WIPO
WO 98/56418 A1	Dec. 17, 1998	WIPO
WO 98/58964 A1	Dec. 30, 1998	WIPO
WO 99/00518 A1	Jan. 7, 1999	WIPO
WO 99/02653 A1	Jan. 21, 1999	WIPO
WO 99/04001 A1	Jan. 28, 1999	WIPO
WO 99/07738 A2	Feb. 18, 1999	WIPO
WO 99/09165 A1	Feb. 25, 1999	WIPO
WO 99/11791 A2	Mar. 11, 1999	WIPO
WO 99/12964 A2	Mar. 18, 1999	WIPO
WO 99/12965 A2	Mar. 18, 1999	WIPO
WO 99/19490 A1	Apr. 22, 1999	WIPO
WO 99/22764 A1	May 14, 1999	WIPO
WO 99/28462 A2	Jun. 10, 1999	WIPO
WO 99/33980 A2	Jul. 8, 1999	WIPO
WO 99/33988 A1	Jul. 8, 1999	WIPO
WO 99/35170 A2	Jul. 15, 1999	WIPO
WO 99/50416 A1	Oct. 7, 1999	WIPO
WO 99/51642 A1	Oct. 14, 1999	WIPO

EXAMINER	DATE CONSIDERED
	<u> </u>

SUBSTITUTE FORM PTO-1449 U.S. DEFARTMENT OF COMMERCE		Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
INFORMATI	ON DISCLOSTIBE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(USC SCVCIAI)	sheets ii newssary)	Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

WO 00/29160 A1 Feb. 24, 2000 WIPO  WO 00/20864 A1 Apr. 13, 2000 WIPO  WO 00/24811 A1 May 4, 2000 WIPO  WO 00/26244 A2 May 11, 2000 WIPO  WO 00/27428 A1 May 18, 2000 WIPO  WO 00/27433 A1 May 18, 2000 WIPO  WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/50633 A1 Oct. 5, 2000 WIPO  WO 00/57795 A1 Nov. 16, 2000 WIPO  WO 00/68778 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Dec. 21, 2000 WIPO  WO 00/56542 A1 Dec. 21, 2000 WIPO  WO 00/56542 A1 Dec. 21, 2000 WIPO	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 00/24811 A1 May 4, 2000 WIPO  WO 00/26244 A2 May 11, 2000 WIPO  WO 00/27428 A1 May 18, 2000 WIPO  WO 00/27433 A1 May 18, 2000 WIPO  WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/5795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Dec. 21, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/09160 A1	Feb. 24, 2000	WIPO
WO 00/26244 A2 May 11, 2000 WIPO  WO 00/27428 A1 May 18, 2000 WIPO  WO 00/27433 A1 May 18, 2000 WIPO  WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/5795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/20864 A1	Apr. 13, 2000	WIPO
WO 00/27428 A1 May 18, 2000 WIPO  WO 00/27433 A1 May 18, 2000 WIPO  WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	· WO 00/24811 A1	May 4, 2000	WIPO
WO 00/27433 A1 May 18, 2000 WIPO  WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/5795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/26244 A2	May 11, 2000	WIPO
WO 00/39295 A1 Jul. 6, 2000 WIPO  WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/27428 A1	May 18, 2000	WIPO
WO 00/42072 A2 Jul. 20, 2000 WIPO  WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/27433 A1	May 18, 2000	WIPO
WO 00/43032 A2 Jul. 27, 2000 WIPO  WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/39295 A1	Jul. 6, 2000	WIPO
WO 00/44788 A1 Aug. 3, 2000 WIPO  WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/678378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/42072 A2	Jul. 20, 2000	·WIPO
WO 00/45836 A1 Aug. 10, 2000 WIPO  WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/43032 A2	Jul. 27, 2000	WIPO
WO 00/50597 A2 Aug. 31, 2000 WIPO  WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/44788 A1	Aug. 3, 2000	WIPO
WO 00/50633 A1 Aug. 31, 2000 WIPO  WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/45836 A1	Aug. 10, 2000	WIPO
WO 00/58362 A1 Oct. 5, 2000 WIPO  WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/50597 A2	Aug. 31, 2000	WIPO
WO 00/67795 A1 Nov. 16, 2000 WIPO  WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/50633 A1	Aug. 31, 2000	WIPO
WO 00/67796 A1 Nov. 16, 2000 WIPO  WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/58362 A1	Oct. 5, 2000	WIPO
WO 00/68378 A1 Nov. 16, 2000 WIPO  WO 00/74718 A1 Dec. 14, 2000 WIPO  WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/67795 A1	Nov. 16, 2000	WIPO
WO 00/74718 A1 Dec. 14, 2000 WIPO WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/67796 A1	Nov. 16, 2000	WIPO
WO 00/76542 A1 Dec. 21, 2000 WIPO	WO 00/68378 A1	Nov. 16, 2000	WIPO
	WO 00/74718 A1	Dec. 14, 2000	WIPO
WO 01/03734 A1 Jan 18 2001 WIDO	WO 00/76542 A1	Dec. 21, 2000	WIPO
VVO 01/03/34 A1   3a1i. 10, 2001   VVIPO	WO 01/03734 A1	Jan. 18, 2001	WIPO

EXAMINER
----------

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODII IED)	TATERTARD HADEWARK OF TOE	Serial No.	10/626,914
INFORMATION DISCLOSURE		Applicant	Anan Chuntharapai et al.
STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN	PATENT OR PUBLIS	SHED FOREIGN PATENT APPLICATION
WO 01/10460 A1	Feb. 15, 2001	WIPO
WO 01/10461 A1	Feb. 15, 2001	WIPO
WO 01/10462 A1	Feb. 15, 2001	WIPO
WO 01/12812 A2	Feb. 22, 2001	WIPO
WO 01/13945 A1	Mar. 1, 2001	WIPO
WO 01/24811 A1	Apr. 12, 2001	WIPO
WO 01/25256 A2	Apr. 12, 2001	WIPO
WO 01/34194 A1	May 17, 2001	WIPO
WO 01/58949 A2	Aug. 16, 2001	WIPO
WO 01/60397 A1	Aug. 23, 2001	WIPO
WO 01/72333 A1	Oct. 4, 2001	WIPO
WO 01/74388 A1	Oct 11, 2001	WIPO
WO 01/77342 A1	Oct. 18, 2001	WIPO
WO 01/80844 A2	Nov. 1, 2001	WIPO
WO 01/96528 A2	Dec. 20, 2001	WIPO
WO 01/97858 A2	Dec. 27, 2001	WIPO
WO 02/02641 A1	Jan. 10, 2002	WIPO
WO 02/04021 A1	Jan. 17, 2002	WIPO
 WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)
WO 02/16412 A2	Feb. 28, 2002	WIPO

EXAMINER	DATE CONSIDERED
1	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 02/1	18620 A2	Mar. 7, 2002	WIPO
WO 02/2	24909 A2	Mar. 28, 2002	WIPO
WO 02/3	34790 A1	May 2, 2002	WIPO
WO 02/3	38766 A2	May 16, 2002	WIPO
WO 02/0	060485 A2	Aug. 8, 2002	WIPO
WO 02/0	060955 A2	Aug. 8, 2002	WIPO
WO 02/0	79255 A1	Oct. 10, 2002	WIPO
WO 02/0	92620 A2	Nov. 21, 2002	WIPO
WO 02/0	094192 A2	Nov. 28, 2002	WIPO
WO 02/0	094852 A2	Nov. 28, 2002	WIPO
WO 02/0	096948 A2	Dec. 5, 2002	WIPO
WO 02/1	102312 A2	Dec. 27, 2002	WIPO
WO 03/0	002607 A1	Jan. 9, 2003	WIPO
WO 03/0	014294 A2	Feb. 20, 2003	WIPO
WO 03/0	024991 A2	Mar. 27, 2003	WIPO ·
WO 03/0	033658 A2	Apr. 24, 2003	WIPO
WO 03/0	035846 A2	May 1, 2003	WIPO
WO 03/0	045421 A1	Jun. 5, 2003	WIPO
WO 03/0	049694 A2	Jun. 19, 2003	WIPO
WO 03/0	055979 A2	Jul. 10, 2003	WIPO

EXAMINER	DATE CONSIDERED
EVANIAIED: Initial siteties appaided at Draw line through siteties	if not in conformance and not considered. Include convert this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN F	PATENT OR PUBLIS	SHED FOREIGN PATENT APPLICATION
 WO 03/061694 A1	Jul. 31, 2003	WIPO
WO 03/068821 A2	Aug. 21, 2003	WIPO
WO 2004/011611 A2	Feb. 5, 2004	WIPO
WO 2004/032828 A2	Apr. 22, 2004	WIPO
 WO 2004/035607 A2	Apr. 29, 2004	WIPO
WO 2004/056312 A2	Jul. 8, 2004	WIPO
WO 2004/081043 A2	Sep. 23, 2004	WIPO
WO 2005/000351 A2	Jan. 6, 2005	WIPO
WO 2005/005462 A2	Jan. 20, 2005	WIPO
WO 2006/052493 A1	May 18, 2006	WIPO
WO 2006/068867 A1	May 29, 2006	WIPO
WO 2006/073941 A2	Jul. 13, 2006	WIPO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citati	on if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
Baldwin, "The NF-кВ and IкВ proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," Cell 73:431-45 (1993).
Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
 Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
Callard et al., "CD40 ligand and its role in X-linked hyper-IgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through cit	ation if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATI	ON BIGGLOGUES	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31 (1986).
Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," <i>Nature</i> 283:666-8 (1980).
Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ," <i>Eur. J. Immunol.</i> 17:689-93 (1987).
Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-xB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include conv of this

SUBSTITUTE FORM PTO-1449		Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATIC	ON DICOLOCUPE	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	July 25, 2003	
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science 261:1328-30 (1993).
Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," Rheumatology 40:205-11 (2001).
Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
GenBank accession number AF046888
GenBank accession number AF136293
GenBank accession number AK008142
GenBank accession number Al250289, XP002206618
GenBank accession number Z99716.4, XP002206619
Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	. 10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	July 25, 2003	
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," <i>Cell</i> 73:447-56 (1993).
Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," <i>Science</i> 273:1864-7 (1996).
Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," J. Immunol. 155:556-67 (1995).
Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," Genome Res. 10:237-43 (2000).
Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-7 (1993).
Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," J. Biol. Chem. 264:14927-34 (1989).
Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).
Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).
Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).
International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DE	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
 Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum</i> . 39:797-809 (1996).
Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).
Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kB2," <i>Immunity</i> 10:515-24 (2002).
Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," <i>Leuk. Res.</i> 11:1119-25 (1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include conv of this	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
Kwon et al., "Single amino acid substitutions of α <sub>1</sub> -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
 Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," Curr. Opin. Immunol. 11:340-5 (1999).
Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
Lane et al., "B cell function in mice transgenic for mCTLA-Hγ1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," Arthritis Rheum. 46:2673-7 (2002).
Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," Arthritis Rheum. 44:S370, Abstract No. 1905 (2001).
Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
 Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the AWySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

		the state of the s
	OTHER DOCUMENTS (INCLUDING AUTHO	R, TITLE, DATE, PLACE OF PUBLICATION)
	Lentz et al., "Bcmd decreases the life span of B-(1998).	2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7
	Lesley et al., "Reduced competitiveness of autoa Immunity 20:441-53 (2004).	antigen-engaged B cells due to increased dependence on BAFF
	Levine and Pestronk, "IgM antibody-related polying Neurology 52:1701-4 (1999).	neuropathies: B-cell depletion chemotherapy using rituximab,"
	Lewis et al., "Cloning and expression of cDNAs f demonstrate one receptor is species specific," P	for two distinct murine tumor necrosis factor receptors roc. Natl. Acad. Sci. USA 88:2830-4 (1991).
	Linsley et al., "Immunosuppression in vivo by a s 257:792-5 (1992).	coluble form of the CTLA-4 T cell activation molecule," Science
	Locksley et al., "The TNF and TNF receptor super (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501
	Loetscher et al., "Molecular cloning and express 61:351-9 (1990).	ion of the human 55 kd tumor necrosis factor receptor," Cell
	Lotz et al., "The nerve growth factor/tumor necro	sis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).
	MacFarlane et al., "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-20 (1997).	
	Mackay and Browning, "BAFF: a fundamental su	rivival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002).
	Mackay et al., "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations," J. Exp. Med. 190:1697-710 (1999).	
	Mackay et al., "BAFF and APRIL: a tutorial on B cell survival," Annu. Rev. Immunol. 21:231-64 (2003).	
	MacLennan, "Germinal centers," Annu. Rev. Immunol. 12:117-39 (1994).	
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," Int. Immunol. 10:1693-702 (1998).	
	Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease," <i>Immunol. Rev.</i> 144:195-223 (1995).	
	Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a molecule related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063-8 (1990).	
	Mandala et al., "Alteration of lymphocyte trafficki 296:346-9 (2002).	ng by sphingosine-1-phosphate receptor agonists," Science
EXAMINER	<u>*                                    </u>	DATE CONSIDERED

	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)  Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and
activates apoptosis and NF-κB," Curr. Biol. 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-kB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," <i>Am. J. Med.</i> 84:817-25 (1988).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through form with the next communication to applicant.	n citation if not in conformance and not considered. Include copy of this

	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH₂-terminal kinase," J. Biol. Chem. 274:15978-81 (1999).
Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," Blood 97:198-204 (2001).
Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
 Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," Eur. J. Immunol. 18:1397-404 (1988).
Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immunol. 31:213-24 (1990).
Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," J. Exp. Med. 197:297-302 (2003).
Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 (1990).
Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," Science 293:2111-4 (2001).
Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 169:147-55 (1996).
Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," <i>Proc. Natl. Acad. Sci. USA</i> 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this	

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
WEST WATER A DIGGLOST OF		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," J. Exp. Med. 189:1747-56 (1999).
Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," Science 277:818-21 (1997).
Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," J. Biol. Chem. 276:6591-604 (2001).
Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," Proc. Natl. Acad. Sci. USA 97:9156-61 (2000).
Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell 89:309-19 (1997).
Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," <i>Cell</i> 66:1133-44 (1991).
Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," <i>J. Immunol.</i> 135:973-9 (1985).
Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," <i>J. Biol. Chem.</i> 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of thi form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODIALTIC	NA DIGG! GOLDE	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE  F BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
 Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κB/lκB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," Science 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," Arthritis Rheum. 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," Virology 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER		DATE CONSIDERED
	XAMINER: Initial citation considered. Draw line through citation with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INICODMATI	ON DISCLOSURE	Applicant	Anan Chuntharapai et al.
STATEMEN	T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
	Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
	Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
	Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," Curr. Biol. 11:1547-52 (2001).
	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
-	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
	Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
	Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
	Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EXA	<b>JAHLA</b>	!EK

SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Attorney Docket No.

50474/017002

Serial No. Applicant 10/626,914

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Use several sheets if necessary) Filing Date

July 25, 2003

Anan Chuntharapai et al.

Group

1644

(37 C.F.R. § 1.98(b))

IDS Filed

August 7, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	3,773,919	Nov. 20, 1973	Boswell et al.
	4,179,337	Dec. 18, 1979	Davis et al.
	4,301,144	Nov. 17, 1981	lwashita et al.
	4,496,689	Jan. 29, 1985	Mitra
	4,640,835	Feb. 3, 1987	Shimizu et al.
	4,670,417	Jun. 2, 1987	Iwasaki et al.
	4,791,192	Dec. 13, 1988	Nakagawa et al.
	4,816,567	Mar. 28, 1989	Cabilly et al.
	4,861,579	Aug. 29, 1989	Meyer et al.
	5,182,196	Jan. 26, 1993	Allet et al.
	5,262,309	Nov. 16, 1993	Nakamura et al.
	5,422,104	Jun. 6, 1995	Fiers et al.
	5,428,130	Jun. 27, 1995	Capon et al.
	5,486,463	Jan. 23, 1996	Lesslauer et al.
	5,500,362	Mar. 19, 1996	Robinson et al.
	5,519,119	May 21, 1996	Yamada et al.
	5,540,926	Jul. 30, 1996	Aruffo et al.
	5,587,457	Dec. 24, 1996	Rathjen et al.
	5,595,721	Jan. 21, 1997	Kaminski et al.
	5,610,279	Mar. 11, 1997	Brockhaus et al.
	5,641,663	Jun. 24, 1997	Garvin et al.
EXAMINER			DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATIO	NA DIDOL COURT	Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE TBY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS				
5,652,353	Jul. 29, 1997	Fiers et al.		
5,677,180	Oct. 14, 1997	Robinson et al.		
5,721,108	Feb. 24, 1998	Robinson et al.		
5,736,137	Apr. 7, 1998	Anderson et al.		
5,776,456	Jul. 7, 1998	Anderson et al.		
5,808,029	Sep. 15, 1998	Brockhaus et al.		
5,821,337	Oct. 13, 1998	Carter et al.		
5,843,398	Dec. 1, 1998	Kaminski et al.		
5,843,439	Dec. 1, 1998	Anderson et al.		
5,849,898	Dec. 15, 1998	Seed et al.		
6,015,542	Jan. 18, 2000	Kaminski et al.		
6,090,365	Jul. 18, 2000	Kaminski et al.		
6,120,767	Sep. 19, 2000	Robinson et al.		
6,171,586	Jan. 9, 2001	Lam et al.		
6,171,787	Jan. 9, 2001	Wiley		
6,194,551	Feb. 27, 2001	Idusogie et al.		
6,224,866	May 1, 2001	Barbera-Guillem		
6,242,195	Jun. 5, 2001	Idusogie et al.		
6,287,537	Sep. 11, 2001	Kaminski et al.		
6,297,022	Oct. 2, 2001	McDonnell et al.		
6,297,367	Oct. 2, 2001	Tribouley		
6,306,393	Oct. 23, 2001	Goldenberg		
6,355,782	Mar. 12, 2002	Zonana et al.		

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
IN ISODNA TO		Applicant	Anan Chuntharapai et al.
STATEMEN	ON DISCLOSURE T BY APPLICANT	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
6,368,596	5	Apr. 9, 2002	Ghetie et al.
6,399,061	i	Jun. 4, 2002	Anderson et al.
6,403,770	)	Jun. 11, 2002	Yu et al.
6,410,391	ı	Jun. 25, 2002	Zelsacher
6,440,694	1	Aug. 27, 2002	Bienkowski et al.
6,455,043	3	Sep. 24, 2002	Grillo-Lopez
6,475,986	5	Nov. 5, 2002	Aggarwal
6,475,987	7	Nov. 5, 2002	Shu
6,506,882	2	Jan. 14, 2003	Yu et al.
6,509,170	)	Jan. 21, 2003	Yu et al.
6,528,624	1	Mar. 4, 2003	Idusogie et al.
6,538,124	1	Mar. 25, 2003	Idusogie et al.
6,541,224	4	Apr. 1, 2003	Yu et al.
6,551,798	5	Apr. 22, 2003	Rubenfield et al.
6,565,827	7	May 20, 2003	Kaminski et al.
6,652,852	2	Nov. 25, 2003	Robinson et al.
6,682,734	4	Jan. 27, 2004	Anderson et al.
6,869,608	5	Маг. 22, 2005	Browning et al.
6,875,846	5	Apr. 5, 2005	Rennert et al.
7,083,785	5	Aug. 1, 2006	Browning et al.
2001/001	8041	Aug. 30, 2001	Hanna et al.
2002/000	4587	Jan. 10, 2002	Miller et al.
2002/000	6404	Jan. 17, 2002	Hanna et al.

**EXAMINER** 

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS		
2002/0009427	Jan. 24, 2002	Wolin et al.
2002/0009444	Jan. 24, 2002	Grillo-Lopez
2002/0012665	Jan. 31, 2002	Hanna
2002/0037852	Mar. 28, 2002	Browning et al.
2002/0041847	Apr. 11, 2002	Goldenberg
2002/0058029	May 16, 2002	Hanna
2002/0081296	Jun. 27, 2002	Theill et al.
2002/0086018	Jul. 4, 2002	Theill et al.
2002/0128488	Sep. 12, 2002	Yamakawa et al.
2002/0136719	Sep. 26, 2002	Shenoy et al.
2002/0165156	Nov. 7, 2002	Browning et al.
2002/0172674	Nov. 21, 2002	Browning et al.
2002/0197255	Dec. 26, 2002	Anderson et al.
2002/0197256	Dec. 26, 2002	Grewal
2003/0012783	Jan. 16, 2003	Kindsvogel
2003/0021781	Jan. 30, 2003	Anderson et al.
2003/0023038	Jan. 30, 2003	Rennert et al.
2003/0026801	Feb. 6, 2003	Weiner et al.
2003/0068664	Apr. 10, 2003	Albitar et al.
2003/0082172	May 1, 2003	Anderson et al.
2003/0082175	May 1, 2003	Schneider et al.
2003/0092164	May 15, 2003	Gross et al.
2003/0095963	May 22, 2003	Anderson et al.

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION	ON DISCLOSING	Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
2003/0095967	May 22, 2003	MacKay et al.	
2003/0099990	May 29, 2003	Hsu	
2003/0103971	Jun. 5, 2003	Hariharan et al.	
2003/0133930	Jul. 17, 2003	Goldenberg et al.	
2003/0147885	Aug. 7, 2003	Anderson et al.	
2003/0157108	Aug. 21, 2003	Presta	
2003/0180292	Sep. 25, 2003	Hanna et al.	
2003/0185796	Oct. 2, 2003	Wolin et al.	
2003/0194743	Oct. 16, 2003	Beltzer et al.	
2003/0219433	Nov. 27, 2003	Hansen et al.	
2003/0219818	Nov. 27, 2003	Bohen et al.	
2004/0093621	May 13, 2004	Shitara et al.	
2005/0070689	Mar. 31, 2005	Dixit et al.	
2005/0095243	May 5, 2005	Chan et al.	
2005/0163775	Jul. 28, 2005	Chan et al.	
2006/0073146	Apr. 6, 2006	Ashkenazi et al.	
2006/0240517	Oct. 26, 2006	Ambrose et al.	
2006/0240519	Oct. 26, 2006	Ambrose et al.	
2006/0240520	Oct. 26, 2006	Ambrose et al.	
09/724,341	Nov. 28, 2000	Ashkenazi et al.	

EXAMINER	 DATE CONSIDE	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
1115001147			Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO —	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
•=	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
-	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
-	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED

(37 C.F.R. § 1.98(b))		Group IDS Filed	1644 August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED) PATENT	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449 U.S. DEF	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
W	VO 98/55620 A1	Dec. 10, 1998	WIPO
W	VO 98/55621 A1	Dec. 10, 1998	WIPO
W	VO 98/56418 A1	Dec. 17, 1998	WIPO
W	VO 98/58964 A1	Dec. 30, 1998	WIPO
W	VO 99/00518 A1	Jan. 7, 1999	WIPO
W	VO 99/02653 A1	Jan. 21, 1999	WIPO
W	VO 99/04001 A1	Jan. 28, 1999	WIPO
v	VO 99/07738 A2	Feb. 18, 1999	WIPO
W	VO 99/09165 A1	Feb. 25, 1999	WIPO
W	VO 99/11791 A2	Mar. 11, 1999	WIPO
v	VO 99/12964 A2	Mar. 18, 1999	WIPO
v	VO 99/12965 A2	Mar. 18, 1999	WIPO
v	VO 99/19490 A1	Apr. 22, 1999	WIPO
v	VO 99/22764 A1	May 14, 1999	WIPO
V	VO 99/28462 A2	Jun. 10, 1999	WIPO
v	VO 99/33980 A2	Jul. 8, 1999	WIPO
V	VO 99/33988 A1	Jul. 8, 1999	WIPO
v	VO 99/35170 A2	Jul. 15, 1999	WIPO
V	VO 99/50416 A1	Oct. 7, 1999	WIPO
V	VO 99/51642 A1	Oct. 14, 1999	WIPO

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered	Draw line through citation if not in conformance and not considered. Include copy of this

	SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
	(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
			Filing Date	July 25, 2003
			Group	1644
	(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN	PATENT OR PUBLIS	HED FOREIGN PATENT APPLICATION
	WO 00/09160 A1	Feb. 24, 2000	WIPO
	WO 00/20864 A1	Apr. 13, 2000	WIPO
	WO 00/24811 A1	May 4, 2000	WIPO
	WO 00/26244 A2	May 11, 2000	WIPO
	WO 00/27428 A1	May 18, 2000	WIPO
	WO 00/27433 A1	May 18, 2000	WIPO
	WO 00/39295 A1	Jul. 6, 2000	WIPO
	WO 00/42072 A2	Jul. 20, 2000	·WIPO
	WO 00/43032 A2	Jul. 27, 2000	WIPO
,	WO 00/44788 A1	Aug. 3, 2000	WIPO
	WO 00/45836 A1	Aug. 10, 2000	WIPO
	WO 00/50597 A2	Aug. 31, 2000	WIPO
	WO 00/50633 A1	Aug. 31, 2000	WIPO
	WO 00/58362 A1	Oct. 5, 2000	WIPO
	WO 00/67795 A1	Nov. 16, 2000	WIPO
	WO 00/67796 A1	Nov. 16, 2000	WIPO
	WO 00/68378 A1	Nov. 16, 2000	WIPO
	WO 00/74718 A1	Dec. 14, 2000	WIPO
	WO 00/76542 A1	Dec. 21, 2000	WIPO
	WO 01/03734 A1	Jan. 18, 2001	WIPO

EXAMINER	DATE CONSIDERED
<b>{</b>	

SUBSTITUTE FORM PTO-1449	MODIFIED)  PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
WO 01/10460 A1	Feb. 15, 2001	WIPO		
WO 01/10461 A1	Feb. 15, 2001	WIPO		
WO 01/10462 A1	Feb. 15, 2001	WIPO		
WO 01/12812 A2	Feb. 22, 2001	WIPO		
WO 01/13945 A1	Mar. 1, 2001	WIPO		
WO 01/24811 A1	Apr. 12, 2001	WIPO		
WO 01/25256 A2	Apr. 12, 2001	WIPO		
WO 01/34194 A1	May 17, 2001	WIPO		
WO 01/58949 A2	Aug. 16, 2001	WIPO		
WO 01/60397 A1	Aug. 23, 2001	WIPO		
WO 01/72333 A1	Oct. 4, 2001	WIPO		
WO 01/74388 A1	Oct 11, 2001	WIPO .		
WO 01/77342 A1	Oct. 18, 2001	WIPO		
WO 01/80844 A2	Nov. 1, 2001	WIPO		
WO 01/96528 A2	Dec. 20, 2001	WIPO		
WO 01/97858 A2	Dec. 27, 2001	WIPO		
WO 02/02641 A1	Jan. 10, 2002	WIPO		
WO 02/04021 A1	Jan. 17, 2002	WIPO		
WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)		
WO 02/16412 A2	Feb. 28, 2002	WIPO		

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
WO 02/18620 A2	Mar. 7, 2002	WIPO	
WO 02/24909 A2	Mar. 28, 2002	WIPO	
WO 02/34790 A1	May 2, 2002	WIPO	
WO 02/38766 A2	May 16, 2002	WIPO	
WO 02/060485 A2	Aug. 8, 2002	WIPO	
WO 02/060955 A2	Aug. 8, 2002	WIPO	
WO 02/079255 A1	Oct. 10, 2002	WIPO	
WO 02/092620 A2	Nov. 21, 2002	WIPO	
WO 02/094192 A2	Nov. 28, 2002	WIPO	
WO 02/094852 A2	Nov. 28, 2002	WIPO	
WO 02/096948 A2	Dec. 5, 2002	WIPO	
WO 02/102312 A2	Dec. 27, 2002	WIPO	
WO 03/002607 A1	Jan. 9, 2003	WIPO	
WO 03/014294 A2	Feb. 20, 2003	WIPO	
WO 03/024991 A2	Mar. 27, 2003	WIPO	
WO 03/033658 A2	Apr. 24, 2003	WIPO	
WO 03/035846 A2	May 1, 2003	WIPO	
WO 03/045421 A1	Jun. 5, 2003	WIPO	
WO 03/049694 A2	Jun. 19, 2003	WIPO	
WO 03/055979 A2	Jul. 10, 2003	WIPO	

EXAMINER	DATE CONSIDERED
EVANABLED 1-W-1-W-1-W-1-W-1-W-1-W-1-W-1-W-1-W-1-W	

SUE	BSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MC	ODIFIED)	D) PATENT AND TRADEMARK OFFICE		10/626,914
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Applicant	Anan Chuntharapai et al.
			Filing Date	July 25, 2003
			Group	1644
(37			IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO 03/061694 A1	Jul. 31, 2003	WIPO
	WO 03/068821 A2	Aug. 21, 2003	WIPO
	WO 2004/011611 A2	Feb. 5, 2004	WIPO
	WO 2004/032828 A2	Apr. 22, 2004	WIPO
	WO 2004/035607 A2	Apr. 29, 2004	WIPO
	WO 2004/056312 A2	Jul. 8, 2004	WIPO ,
	WO 2004/081043 A2	Sep. 23, 2004	WIPO
	WO 2005/000351 A2	Jan. 6, 2005	WIPO
	WO 2005/005462 A2	Jan. 20, 2005	WIPO
	WO 2006/052493 A1	May 18, 2006	WIPO
	WO 2006/068867 A1	May 29, 2006	WIPO
	WO 2006/073941 A2	Jul. 13, 2006	WIPO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citat form with the next communication to applicant.	ion if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
Baldwin, "The NF-κB and IκB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," Cell 87:845-55 (1996).
Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
 Callard et al., "CD40 ligand and its role in X-linked hyper-lgM syndrome," Immunol. Today 14:559-64 (1993).

EXAMINER		

DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31 (1986).
Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
 Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," <i>Nature</i> 283:666-8 (1980).
Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-52 (2003).
Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ," Eur. J. Immunol. 17:689-93 (1987).
Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum.</i> 46:2029-33 (2002).
Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," J. Exp. Med. 192:953-64 (2000).
Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science 261:1328-30 (1993).
	Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
	Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," Rheumatology 40:205-11 (2001).
	Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
	Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> 446:S197 (2002).
	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
	Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
	Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
	Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
-	Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
	Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
	GenBank accession number AF046888
4	GenBank accession number AF136293
	GenBank accession number AK008142
	GenBank accession number Al250289, XP002206618
•	GenBank accession number Z99716.4, XP002206619
	Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
	Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER		DATE CONSIDERED
	EXAMINER: Initial citation considered. Draw line through cit	ation if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449 U.S. DI	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," <i>Cell</i> 73:447-56 (1993).
Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," Immunology 65:73-9 (1988).
Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," J. Exp. Med. 189:1017-20 (1999).
Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," Science 273:1864-7 (1996).
Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," <i>J. Cell. Biochem.</i> (abstract only) Supplement 15F:113 (P424) (1991).
Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," J. Immunol. 155:556-67 (1995).
Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," Genome Res. 10:237-43 (2000).
Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMME		Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-7 (1993).
Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)," J. Biol. Chem. 264:14927-34 (1989).
Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986).
Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).
Hoogenboom et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," Mol. Immunol. 28:1027-37 (1991).
Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5," Mol. Cell 4:563-71 (1999).
Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <i>J. Immunol.</i> 164:4178-84 (2000).
International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>J. Immunol.</i> 154:3310-9 (1995).
Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449 U.S. DEPARTME	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Johnson and Chiswell, "Human antibody engineering," Curr. Opin. Struc. Biol. 3:564-71 (1993).
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum.</i> 39:797-809 (1996).
Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).
Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).
Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," Expert Opin. Ther. Targets 7:115-23 (2003).
Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol</i> . 163:5358-66 (1999).
Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation," <i>J. Immunol.</i> 160:4788-95 (1998).
Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation," <i>Immunity</i> 1:167-78 (1994).
Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).
Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res. 60:1021-7 (2000).
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> 97:3370-5 (2000).
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," Leuk. Res. 11:1119-25 (1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," <i>J. Immunol. Methods</i> 156:9-17 (1992).
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (1996).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Kong et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> 397:315-23 (1999).
Kong et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," <i>Nature</i> 402:304-9 (1999).
Krammer et al., "Regulation of apoptosis in the immune system," Curr. Opin. Immunol. 6:279-89 (1994).
Kwon et al., "Single amino acid substitutions of $\alpha_1$ -antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> 269:9627-31 (1994).
Kwon et al., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," Curr. Opin. Immunol. 11:340-5 (1999).
Laabi and Strasser, "Lymphocyte survival – ignorance is BLyS," Science 289:883-4 (2000).
Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-904 (1992).
Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22:1147-54 (1994).
Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell 93:165-76 (1998).
Lane et al., "B cell function in mice transgenic for mCTLA-Hy1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4* T cells," <i>J. Exp. Med.</i> 179:819-30 (1994).
Leandro et al., "An open study of B lymphocyte depletion in systemic lupus erythematosus," <i>Arthritis Rheum</i> . 46:2673-7 (2002).
Leandro et al., "B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response," <i>Arthritis Rheum.</i> 44:S370, Abstract No. 1905 (2001).
Leandro et al., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion," Ann. Rheum. Dis. 61:883-8 (2002).
Ledbetter et al., "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5," Crit. Rev. Immunol. 17:427-35 (1997).
Lenschow et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol. 14:233-58 (1996).
Lentz et al., "Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the AWySnJ mouse," J. Immunol. 157:598-606 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE	· I	
	PATENT AND TRADEMARK OFFICE		10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	257:792-5 (1992).	arfamilies: integrating mammalian history." Cell 104:497-504		
	Locksley et al., "The TNF and TNF receptor super (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501		
	<u>`</u>	ion of the human 55 kd tumor necrosis factor receptor," Cell		
	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family," J. Leukocyte Biol. 60:1			
	MacFarlane et al., "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TF Biol. Chem. 272:25417-20 (1997).			
	Mackay and Browning, "BAFF: a fundamental survival factor for B cells," Nature Rev. Immunol. 2			
	Mackay et al., "Mice transgenic for BAFF develo J. Exp. Med. 190:1697-710 (1999).	p lymphocytic disorders along with autoimmune manifestations,"		
	Mackay et al., "BAFF and APRIL: a tutorial on B cell survival," Annu. Rev. Immunol. 21:231-64 (200			
MacLennan, "Germinal centers," Annu. Rev. Immunol. 12:117-39 (1994).		nunol. 12:117-39 (1994).		
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necessary factor receptor superfamily," Int. Immunol. 10:1693-702 (1998).			
	Maini et al., "Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid dis <i>Immunol. Rev.</i> 144:195-223 (1995).  Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063-8 (1990).			
•				
<del></del>	Mandala et al., "Alteration of lymphocyte trafficki 296:346-9 (2002).	ng by sphingosine-1-phosphate receptor agonists," Science		

(37 C.F.R. § 1.98(b))		Group IDS Filed	1644 August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κΒ," <i>Curr. Biol.</i> 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-κB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69th Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med. 84:817-25 (1988).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No. 50474/017002  Serial No. 10/626,914	
	PATENT AND TRADEMARK OFFICE		10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-кВ, and c-Jun NH <sub>2</sub> -terminal kinase," <i>J. Biol. Chem.</i> 274:15978-81 (1999).
Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," Blood 97:198-204 (2001).
Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
 Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation	n if not in conformance and not considered. Include copy of this	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	lo. 50474/017002
	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," <i>Eur. J. Immunol.</i> 18:1397-404 (1988).
Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immunol. 31:213-24 (1990).
Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994).
Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," <i>J. Exp. Med.</i> 197:297-302 (2003).
Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 (1990).
Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," Science 293:2111-4 (2001).
Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," <i>Gene</i> 169:147-55 (1996).
Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," Proc. Natl. Acad. Sci. USA 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	Attorney Docket No. 50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
WEST WEST DISCUSSION		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
	Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative premRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
	Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
	Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," Science 277:818-21 (1997).
	Shields et al., "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR*," <i>J. Biol. Chem.</i> 276:6591-604 (2001).
	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
	Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," Proc. Natl. Acad. Sci. USA 97:9156-61 (2000).
	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell 89:309-19 (1997).
	Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," Biochem. Biophys. Res. Commun. 176:335-42 (1991).
	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," Cell 73:1349-60 (1993).
	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
	Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).
r — —	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citatio form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	J.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	(MODIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
		Applicant	Anan Chuntharapai et al.
STATEMENT	DN DISCLOSURE  F BY APPLICANT  hoods if passesses	Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
	Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," Cell 66:1133-44 (1991).
	Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
	Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
	Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
	Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," J. Immunol. 135:973-9 (1985).
	Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
	Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
,	Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
	Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
	Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
	Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," <i>Virology</i> 160:20-30 (1987).
	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
	Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," J. Biol. Chem. 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citatio form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κΒ/IκΒ family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," <i>Science</i> 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," Arthritis Rheum. 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," Immunity 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," Virology 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724-30 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citatic form with the next communication to applicant.	on if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/626,914
INFORMATION DIRECTOR		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several abouts if passesses)		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> 262:4429-32 (1987).
Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-52 (2001).
Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nat. Immunol.</i> 1:252-6 (2000).
Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EX	ΑM	IN	FR
-	~~		-

AUG 11 2008 W

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No. 504

50474/017002

Serial No.

10/626,914

INFORMATION DISCLOSURE

Applicant

Anan Chuntharapai et al.

STATEMENT BY APPLICANT (Use several sheets if necessary)

Filing Date

July 25, 2003

Group

1644

(37 C.F.R. § 1.98(b))

**IDS** Filed

August 7, 2008

U.S. PATENT DOCUMENTS				
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
	3,773,919	Nov. 20, 1973	Boswell et al.	
	4,179,337	Dec. 18, 1979	Davis et al.	
	4,301,144	Nov. 17, 1981	Iwashita et al.	
	4,496,689	Jan. 29, 1985	Mitra	
	4,640,835	Feb. 3, 1987	Shimizu et al.	
	4,670,417	Jun. 2, 1987	lwasaki et al.	
	4,791,192	Dec. 13, 1988	Nakagawa et al.	
	4,816,567	Mar. 28, 1989	Cabilly et al.	
	4,861,579	Aug. 29, 1989	Meyer et al.	
	5,182,196	Jan. 26, 1993	Allet et al.	
	5,262,309	Nov. 16, 1993	Nakamura et al.	
	5,422,104	Jun. 6, 1995	Fiers et al.	
	5,428,130	Jun. 27, 1995	Capon et al.	
	5,486,463	Jan. 23, 1996	Lesslauer et al.	
	5,500,362	Mar. 19, 1996	Robinson et al.	
	5,519,119	May 21, 1996	Yamada et al.	
	5,540,926	Jul. 30, 1996	Aruffo et al.	
	5,587,457	Dec. 24, 1996	Rathjen et al.	
	5,595,721	Jan. 21, 1997	Kaminski et al.	
	5,610,279	Mar. 11, 1997	Brockhaus et al.	
	5,641,663	Jun. 24, 1997	Garvin et al.	
EXAMINER			DATE CONSIDERED	

STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date Group	July 25, 2003 1644
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Filing Date	Anan Chuntharapai et al. July 25, 2003
(MODIFIED)		Serial No.	10/626,914
SUBSTITUTE FORM PTO-1449 (MODIFIED)			50474/017002

5,652,353       Jul. 29, 1997       Fiers et al.         5,677,180       Oct. 14, 1997       Robinson et al.         5,721,108       Feb. 24, 1998       Robinson et al.	
5,721,108 Feb. 24, 1998 Robinson et al.	
5,736,137 Apr. 7, 1998 Anderson et al.	
5,776,456 Jul. 7, 1998 Anderson et al.	
5,808,029 Sep. 15, 1998 Brockhaus et al.	
5,821,337 Oct. 13, 1998 Carter et al.	
5,843,398 Dec. 1, 1998 Kaminski et al.	
5,843,439 Dec. 1, 1998 Anderson et al.	
5,849,898 Dec. 15, 1998 Seed et al.	
6,015,542 Jan. 18, 2000 Kaminski et al.	
6,090,365 Jul. 18, 2000 Kaminski et al.	
6,120,767 Sep. 19, 2000 Robinson et al.	
6,171,586 Jan. 9, 2001 Lam et al.	
6,171,787 Jan. 9, 2001 Wiley	
6,194,551 Feb. 27, 2001 Idusogie et al.	
6,224,866 May 1, 2001 Barbera-Guillem	
6,242,195 Jun. 5, 2001 Idusogie et al.	
6,287,537 Sep. 11, 2001 Kaminski et al.	
6,297,022 Oct. 2, 2001 McDonnell et al.	
6,297,367 Oct. 2, 2001 Tribouley	
6,306,393 Oct. 23, 2001 Goldenberg	
6,355,782 Mar. 12, 2002 Zonana et al.	

EXAM	IIN	ER
------	-----	----

(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Group	1644
		Filing Date	July 25, 2003
		Applicant	Anan Chuntharapai et al.
(MODIFIED)	MODIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002

6,368,596       Apr. 9, 2002       Ghetie et al.         6,399,061       Jun. 4, 2002       Anderson et al.         6,403,770       Jun. 11, 2002       Yu et al.         6,410,391       Jun. 25, 2002       Zelsacher         6,440,694       Aug. 27, 2002       Bienkowski et al.         6,455,043       Sep. 24, 2002       Grillo-Lopez         6,475,986       Nov. 5, 2002       Aggarwal         6,475,987       Nov. 5, 2002       Shu         6,506,882       Jan. 14, 2003       Yu et al.         6,599,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,689,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.	 U.S. PATENT DOCUMENTS			
6,403,770 Jun. 11, 2002 Yu et al. 6,410,391 Jun. 25, 2002 Zelsacher 6,440,694 Aug. 27, 2002 Bienkowski et al. 6,455,043 Sep. 24, 2002 Grillo-Lopez 6,475,986 Nov. 5, 2002 Aggarwal 6,475,987 Nov. 5, 2002 Shu 6,506,882 Jan. 14, 2003 Yu et al. 6,509,170 Jan. 21, 2003 Yu et al. 6,528,624 Mar. 4, 2003 Idusogie et al. 6,538,124 Mar. 25, 2003 Idusogie et al. 6,541,224 Apr. 1, 2003 Yu et al. 6,551,795 Apr. 22, 2003 Rubenfield et al. 6,665,827 May 20, 2003 Karninski et al. 6,662,852 Nov. 25, 2003 Robinson et al. 6,682,734 Jan. 27, 2004 Anderson et al. 6,889,605 Mar. 22, 2005 Browning et al. 7,083,785 Aug. 1, 2006 Browning et al. 2001/0018041 Aug. 30, 2001 Hanna et al.	 6,368,596	Apr. 9, 2002	Ghetie et al.	
6,410,391 Jun. 25, 2002 Zelsacher 6,440,694 Aug. 27, 2002 Bienkowski et al. 6,455,043 Sep. 24, 2002 Grillo-Lopez 6,475,986 Nov. 5, 2002 Aggarwal 6,475,987 Nov. 5, 2002 Shu 6,506,882 Jan. 14, 2003 Yu et al. 6,509,170 Jan. 21, 2003 Idusogie et al. 6,528,624 Mar. 4, 2003 Idusogie et al. 6,538,124 Apr. 1, 2003 Yu et al. 6,541,224 Apr. 1, 2003 Yu et al. 6,551,795 Apr. 22, 2003 Rubenfield et al. 6,565,827 May 20, 2003 Kaminski et al. 6,652,852 Nov. 25, 2003 Robinson et al. 6,682,734 Jan. 27, 2004 Anderson et al. 6,869,605 Mar. 22, 2005 Rennert et al. 7,083,785 Aug. 1, 2006 Browning et al. 2001/0018041 Aug. 30, 2001 Hanna et al.	 6,399,061	Jun. 4, 2002	Anderson et al.	
6,440,694 Aug. 27, 2002 Bienkowski et al. 6,455,043 Sep. 24, 2002 Grillo-Lopez 6,475,986 Nov. 5, 2002 Aggarwal 6,475,987 Nov. 5, 2002 Shu 6,506,882 Jan. 14, 2003 Yu et al. 6,509,170 Jan. 21, 2003 Yu et al. 6,528,624 Mar. 4, 2003 Idusogie et al. 6,538,124 Mar. 25, 2003 Idusogie et al. 6,541,224 Apr. 1, 2003 Yu et al. 6,551,795 Apr. 22, 2003 Rubenfield et al. 6,665,827 May 20, 2003 Kaminski et al. 6,682,734 Jan. 27, 2004 Anderson et al. 6,689,605 Mar. 22, 2005 Browning et al. 6,875,846 Apr. 5, 2005 Rennert et al. 7,083,785 Aug. 1, 2006 Browning et al. 2001/0018041 Aug. 30, 2001 Hanna et al.	6,403,770	Jun. 11, 2002	Yu et al.	
6,455,043       Sep. 24, 2002       Grillo-Lopez         6,475,986       Nov. 5, 2002       Aggarwal         6,475,987       Nov. 5, 2002       Shu         6,506,882       Jan. 14, 2003       Yu et al.         6,509,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	 6,410,391	Jun. 25, 2002	Zelsacher	
6,475,986       Nov. 5, 2002       Aggarwal         6,475,987       Nov. 5, 2002       Shu         6,506,882       Jan. 14, 2003       Yu et al.         6,509,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,440,694	Aug. 27, 2002	Bienkowski et al.	
6,475,987       Nov. 5, 2002       Shu         6,506,882       Jan. 14, 2003       Yu et al.         6,509,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,455,043	Sep. 24, 2002	Grillo-Lopez	
6,506,882       Jan. 14, 2003       Yu et al.         6,509,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,475,986	Nov. 5, 2002	Aggarwal	
6,509,170       Jan. 21, 2003       Yu et al.         6,528,624       Mar. 4, 2003       Idusogie et al.         6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,475,987	Nov. 5, 2002	Shu	
6,528,624 Mar. 4, 2003 Idusogie et al. 6,538,124 Mar. 25, 2003 Idusogie et al. 6,541,224 Apr. 1, 2003 Yu et al. 6,551,795 Apr. 22, 2003 Rubenfield et al. 6,565,827 May 20, 2003 Kaminski et al. 6,652,852 Nov. 25, 2003 Robinson et al. 6,682,734 Jan. 27, 2004 Anderson et al. 6,869,605 Mar. 22, 2005 Browning et al. 6,875,846 Apr. 5, 2005 Rennert et al. 7,083,785 Aug. 1, 2006 Browning et al. 2001/0018041 Aug. 30, 2001 Hanna et al.	6,506,882	Jan. 14, 2003	Yu et al.	
6,538,124       Mar. 25, 2003       Idusogie et al.         6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,509,170	Jan. 21, 2003	Yu et al.	
6,541,224       Apr. 1, 2003       Yu et al.         6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,528,624	Mar. 4, 2003	Idusogie et al.	
6,551,795       Apr. 22, 2003       Rubenfield et al.         6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,538,124	Mar. 25, 2003	Idusogie et al.	
6,565,827       May 20, 2003       Kaminski et al.         6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,541,224	Apr. 1, 2003	Yu et al.	
6,652,852       Nov. 25, 2003       Robinson et al.         6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,551,795	Apr. 22, 2003	Rubenfield et al.	
6,682,734       Jan. 27, 2004       Anderson et al.         6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,565,827	May 20, 2003	Kaminski et al.	
6,869,605       Mar. 22, 2005       Browning et al.         6,875,846       Apr. 5, 2005       Rennert et al.         7,083,785       Aug. 1, 2006       Browning et al.         2001/0018041       Aug. 30, 2001       Hanna et al.         2002/0004587       Jan. 10, 2002       Miller et al.	6,652,852	Nov. 25, 2003	Robinson et al.	
6,875,846 Apr. 5, 2005 Rennert et al.  7,083,785 Aug. 1, 2006 Browning et al.  2001/0018041 Aug. 30, 2001 Hanna et al.  2002/0004587 Jan. 10, 2002 Miller et al.	6,682,734	Jan. 27, 2004	Anderson et al.	
7,083,785 Aug. 1, 2006 Browning et al.  2001/0018041 Aug. 30, 2001 Hanna et al.  2002/0004587 Jan. 10, 2002 Miller et al.	6,869,605	Mar. 22, 2005	Browning et al.	
2001/0018041 Aug. 30, 2001 Hanna et al. 2002/0004587 Jan. 10, 2002 Miller et al.	6,875,846	Apr. 5, 2005	Rennert et al.	
2002/0004587 Jan. 10, 2002 Miller et al.	7,083,785	Aug. 1, 2006	Browning et al.	
	2001/0018041	Aug. 30, 2001	Hanna et al.	
2002/0006404 Jan. 17, 2002 Hanna et al.	2002/0004587	Jan. 10, 2002	Miller et al.	
	2002/0006404	Jan. 17, 2002	Hanna et al.	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	DDIFIED) PATENT AND TRADEMARK OFFICE		10/626,914
INFORMATION DIOCEOURE		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
2002/0009427	Jan. 24, 2002	Wolin et al.	
2002/0009444	Jan. 24, 2002	Grillo-Lopez	
2002/0012665	Jan. 31, 2002	Hanna	
2002/0037852	Mar. 28, 2002	Browning et al.	
2002/0041847	Apr. 11, 2002	Goldenberg	
2002/0058029	May 16, 2002	Hanna	
2002/0081296	Jun. 27, 2002	Theill et al.	
2002/0086018	Jul. 4, 2002	Theill et al.	
2002/0128488	Sep. 12, 2002	Yamakawa et al.	
2002/0136719	Sep. 26, 2002	Shenoy et al.	
2002/0165156	Nov. 7, 2002	Browning et al.	
2002/0172674	Nov. 21, 2002	Browning et al.	
2002/0197255	Dec. 26, 2002	Anderson et al.	
2002/0197256	Dec. 26, 2002	Grewal	
2003/0012783	Jan. 16, 2003	Kindsvogel	
2003/0021781	Jan. 30, 2003	Anderson et al.	
2003/0023038	Jan. 30, 2003	Rennert et al.	
2003/0026801	Feb. 6, 2003	Weiner et al.	
2003/0068664	Apr. 10, 2003	Albitar et al.	
2003/0082172	May 1, 2003	Anderson et al.	
2003/0082175	May 1, 2003	Schneider et al.	
2003/0092164	May 15, 2003	Gross et al.	
2003/0095963	May 22, 2003	Anderson et al.	

<b>EXAMINER</b>	
-----------------	--

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

U.S. PATENT DOCUMENTS			
2003/0095967	May 22, 2003	MacKay et al.	
2003/0099990	May 29, 2003	Hsu	
2003/0103971	Jun. 5, 2003	Hariharan et al.	
2003/0133930	Jul. 17, 2003	Goldenberg et al.	
2003/0147885	Aug. 7, 2003	Anderson et al.	
2003/0157108	Aug. 21, 2003	Presta	
2003/0180292	Sep. 25, 2003	Hanna et al.	
2003/0185796	Oct. 2, 2003	Wolin et al.	
2003/0194743	Oct. 16, 2003	Beltzer et al.	
2003/0219433	Nov. 27, 2003	Hansen et al.	
2003/0219818	Nov. 27, 2003	Bohen et al.	
2004/0093621	May 13, 2004	Shitara et al.	
2005/0070689	Mar. 31, 2005	Dixit et al.	
2005/0095243	May 5, 2005	Chan et al.	
2005/0163775	Jul. 28, 2005	Chan et al.	
2006/0073146	Apr. 6, 2006	Ashkenazi et al.	
2006/0240517	Oct. 26, 2006	Ambrose et al.	
2006/0240519	Oct. 26, 2006	Ambrose et al.	
2006/0240520	Oct. 26, 2006	Ambrose et al.	
09/724,341	Nov. 28, 2000	Ashkenazi et al.	

EXAMINER		
----------	--	--

	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED) P/	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 307 247 A2	Mar. 15, 1989	EPO	
	0 330 199 A1	Aug. 30, 1989	EPO	
	0 332 865 A2	Sep. 20, 1989	EPO	
	0 417 563 B1	Mar. 3, 1990	EPO	
	0 869 180 A1	Oct. 7, 1998	EPO	
	0 870 827 A2	Oct. 14, 1998	EPO	
	0 911 633 A1	Apr. 28, 1999	EPO	
	WO 95/03770 A1	Feb. 9, 1995	WIPO	
	WO 97/01633 A1	Jan. 16, 1997	WIPO	
	WO 97/25428 A1	Jul. 17, 1997	WIPO	
	WO 97/33902 A1	Sep. 18, 1997	WIPO	
	WO 98/18921 A1	May 7, 1998	WIPO	
	WO 98/27114 A2	Jun. 25, 1998	WIPO	
	WO 98/28426 A2	Jul. 2, 1998	WIPO	
-	WO 98/32856 A1	Jul. 30, 1998	WIPO	
	WO 98/35986 A1	Aug. 20, 1998	WIPO	
	WO 98/41629 A2	Sep. 24, 1998	WIPO	
	WO 98/46643 A1	Oct. 22, 1998	WIPO	
	WO 98/46751 A1	Oct. 22, 1998	WIPO	
-	WO 98/51793 A1	Nov. 19, 1998	WIPO	

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449 L	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 98/55620 A1	Dec. 10, 1998	WIPO
WO 98/55621 A1	Dec. 10, 1998	WIPO
WO 98/56418 A1	Dec. 17, 1998	WIPO
WO 98/58964 A1	Dec. 30, 1998	WIPO
WO 99/00518 A1	Jan. 7, 1999	WIPO
WO 99/02653 A1	Jan. 21, 1999	WIPO
WO 99/04001 A1	Jan. 28, 1999	WIPO
WO 99/07738 A2	Feb. 18, 1999	WIPO
WO 99/09165 A1	Feb. 25, 1999	WIPO
WO 99/11791 A2	Mar. 11, 1999	WIPO
WO 99/12964 A2	Mar. 18, 1999	WIPO
WO 99/12965 A2	Mar. 18, 1999	WIPO
WO 99/19490 A1	Арг. 22, 1999	WIPO
WO 99/22764 A1	May 14, 1999	WIPO
WO 99/28462 A2	Jun. 10, 1999	WIPO
WO 99/33980 A2	Jul. 8, 1999	WIPO
WO 99/33988 A1	Jul. 8, 1999	WIPO
WO 99/35170 A2	Jul. 15, 1999	WIPO
WO 99/50416 A1	Oct. 7, 1999	WIPO
WO 99/51642 A1	Oct. 14, 1999	WIPO

EXAMINER	DATE CONSIDERED
EVANUED LIVE WAS A CONTRACT OF THE STATE OF	

(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008	
	(Use several sheets if necessary)		Group	1644
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Lieu covered about if processor)		Filing Date	July 25, 2003	
			Applicant	Anan Chuntharapai et al.
(MOD	SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
1			Attorney Docket No.	50474/017002

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 00/09160 A1 Feb	o. 24, 2000	WIPO
WO 00/20864 A1 Apr	r. 13, 2000	WIPO
WO 00/24811 A1 Ma	y 4, 2000	WIPO
WO 00/26244 A2 Ma	y 11, 2000	WIPO
WO 00/27428 A1 Ma	y 18, 2000	WIPO
WO 00/27433 A1 Ma	y 18, 2000	WIPO
WO 00/39295 A1 Jul.	. 6, 2000	WIPO
WO 00/42072 A2 Jul.	. 20, 2000	:WIPO
WO 00/43032 A2 Jul.	. 27, 2000	WIPO
WO 00/44788 A1 Aug	g. 3, 2000	WIPO
WO 00/45836 A1 Aug	g. 10, 2000	WIPO
WO 00/50597 A2 Aug	g. 31, 2000	WIPO
WO 00/50633 A1 Aug	g. 31, 2000	WIPO
WO 00/58362 A1 Oct	t. 5, 2000	WIPO
WO 00/67795 A1 Nov	v. 16, 2000	WIPO
WO 00/67796 A1 Nov	v. 16, 2000	WIPO
WO 00/68378 A1 Nov	v. 16, 2000	WIPO
WO 00/74718 A1 Dec	c. 14, 2000	WIPO
WO 00/76542 A1 Dec	c. 21, 2000	WIPO
WO 01/03734 A1 Jan	n. 18, 2001	WIPO

EXAMINER	DATE CONSIDERED
	<u> </u>

	ON DISCLOSURE	Applicant	Anan Chuntharapai et al. July 25, 2003
STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 01/10460 A1	Feb. 15, 2001	WIPO
WO 01/10461 A1	Feb. 15, 2001	WIPO
WO 01/10462 A1	Feb. 15, 2001	WIPO .
WO 01/12812 A2	Feb. 22, 2001	WIPO
WO 01/13945 A1	Mar. 1, 2001	WIPO
WO 01/24811 A1	Apr. 12, 2001	WIPO
WO 01/25256 A2	Apr. 12, 2001	WIPO
WO 01/34194 A1	May 17, 2001	WIPO
WO 01/58949 A2	Aug. 16, 2001	WIPO
WO 01/60397 A1	Aug. 23, 2001	WIPO
WO 01/72333 A1	Oct. 4, 2001	WIPO
WO 01/74388 A1	Oct 11, 2001	WIPO
WO 01/77342 A1	Oct. 18, 2001	WIPO
WO 01/80844 A2	Nov. 1, 2001	WIPO
WO 01/96528 A2	Dec. 20, 2001	WIPO
WO 01/97858 A2	Dec. 27, 2001	WIPO
 WO 02/02641 A1	Jan. 10, 2002	WIPO
 WO 02/04021 A1	Jan. 17, 2002	WIPO
WO 02/16312 A2	Feb. 28, 2002	WIPO (English language abstract)
WO 02/16412 A2	Feb. 28, 2002	WIPO ·

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	FOREIGN	PATENT OR PUBLIS	SHED FOREIGN PATENT APPLICATION
	WO 02/18620 A2	Mar. 7, 2002	WIPO
	WO 02/24909 A2	Mar. 28, 2002	WIPO
	WO 02/34790 A1	May 2, 2002	WIPO
	WO 02/38766 A2	May 16, 2002	WIPO
	WO 02/060485 A2	Aug. 8, 2002	WIPO
	WO 02/060955 A2	Aug. 8, 2002	WIPO
	WO 02/079255 A1	Oct. 10, 2002	WIPO
•	WO 02/092620 A2	Nov. 21, 2002	WIPO
	WO 02/094192 A2	Nov. 28, 2002	WIPO
	WO 02/094852 A2	Nov. 28, 2002	WIPO
	WO 02/096948 A2	Dec. 5, 2002	WIPO
-	WO 02/102312 A2	Dec. 27, 2002	WIPO
	WO 03/002607 A1	Jan. 9, 2003	WIPO
	WO 03/014294 A2	Feb. 20, 2003	WIPO
	WO 03/024991 A2	Mar. 27, 2003	WIPO
	WO 03/033658 A2	Apr. 24, 2003	WIPO
	WO 03/035846 A2	May 1, 2003	WIPO
	WO 03/045421 A1	Jun. 5, 2003	WIPO
-	WO 03/049694 A2	Jun. 19, 2003	WIPO
	WO 03/055979 A2	Jul. 10, 2003	WIPO

EXAMINER	DATE CONSIDERED

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION		
WO 03/061694 A1	Jul. 31, 2003	WIPO
WO 03/068821 A2	Aug. 21, 2003	WIPO
WO 2004/011611 A2	Feb. 5, 2004	WIPO
WO 2004/032828 A2	Apr. 22, 2004	WIPO
WO 2004/035607 A2	Apr. 29, 2004	WIPO
WO 2004/056312 A2	Jul. 8, 2004	WIPO
WO 2004/081043 A2	Sep. 23, 2004	WIPO
WO 2005/000351 A2	Jan. 6, 2005	WIPO
WO 2005/005462 A2	Jan. 20, 2005	WIPO
WO 2006/052493 A1	May 18, 2006	WIPO
WO 2006/068867 A1	May 29, 2006	WIPO
WO 2006/073941 A2	Jul. 13, 2006	WIPO

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-lgM syndrome," Science 259:990-3 (1993).
	Amakawa et al., "The Hodgkin disease antigen CD30 is crucial for antigen induced death of developing T cells," Cold Spring Harbor Laboratory Symposium on Programmed Cell Death, Abstract No. 10 (1995).
	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation," <i>Blood</i> 63:1424-33 (1984).
_	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-9 (1997).
	Anolik and Aringer, "New treatments for SLE: cell-depleting and anti-cytokine therapies," Best Pract. Res. Clin. Rheumatol. 19:859-78 (2005).

EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered	Draw line through citation	if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Armitage et al., "Molecular and biological characterization of a murine ligand for CD40," Nature 357:80-2 (1992).
Aruffo et al., "CD44 is the principal cell surface receptor for hyaluronate," Cell 61:1303-13 (1990).
Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome," Cell 72:291-300 (1993).
Ashkenazi and Dixit, "Death receptors: signaling and modulation," Science 281:1305-8 (1998).
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-9 (1991).
Bachmann et al., "TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation," <i>J. Exp. Med.</i> 189:1025-31 (1999).
Baldwin, "The NF-kB and IkB proteins: new discoveries and insights," Annu. Rev. Immunol. 14:649-83 (1996).
Banner et al., "Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation," <i>Cell</i> 73:431-45 (1993).
Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," Proc. Natl. Acad. Sci. USA 91:3809-13 (1994).
Batten et al., "BAFF mediates survival of peripheral immature B lymphocytes", J. Exp. Med. 192:1453-65 (2000).
Bodmer et al., "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88 (1997).
Bodmer et al., "The molecular architecture of the TNF superfamily," Trends Biochem. Sci. 27:19-26 (2002).
Bost and Pascual, "Antibodies against a peptide sequence within the HIV envelope protein cross reacts with human interleukin-2," <i>Immunol. Invest.</i> 17:577-86 (1988).
Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-31 (1990).
Brojatsch et al., "CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis," <i>Cell</i> 87:845-55 (1996).
Browning et al., "Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface," <i>Cell</i> 72:847-56 (1993).
Callard et al., "CD40 ligand and its role in X-linked hyper-lgM syndrome," Immunol. Today 14:559-64 (1993).
 L

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest 54:26-31 (1986).
Chamow and Ashkenazi, "Immunoadhesins: principles and applications," Trends Biotechnol. 14:52-60 (1996).
Cheema et al., "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases," <i>Arthritis Rheum.</i> 44:1313-9 (2001).
Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis," <i>J. Biol. Chem.</i> 272:32401-10 (1997).
 Chinnaiyan et al., "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95," Science 274:990-2 (1996).
Clark and Ledbetter, "Structure, function, and genetics of human B cell-associated surface molecules," Adv. Cancer Res. 52:81-149 (1989).
Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666 (1980).
Cragg et al., "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," Blood 101:1045-52 (2003).
Craxton et al., "A role for zTNF4/APRIL in the co-stimulation of B cell proliferation by macrophages," Experimental Biology 2002: Meeting Abstracts, Abstract 516.51:A704-5 (2002).
Cyster, "B cells on the front line," Nat. Immunol. 1:9-10 (2000).
Dealtry et al., "DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ Eur. J. Immunol. 17:689-93 (1987).
Degli-Esposti et al., "The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain," <i>Immunity</i> 7:813-20 (1997).
Degli-Esposti et al., "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL recept family," <i>J. Exp. Med.</i> 186:1165-70 (1997).
De Vita et al., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells," <i>Arthritis Rheum</i> . 46:2029-33 (2002).
Do et al., "Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192:953-64 (2000).
Domingues, "Rational design strategies to improve cytokine foldability and minimization of a functional motif: the IL-4 case," Thesis, University of Utrecht, p. 48, line 25 through p. 51, line 6; page 94, Table III (May 26, 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation	if not in conformance and not considered. Include copy of this

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002	
(MODIFIED) PA	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	July 25, 2003	
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," <i>Science</i> 261:1328-30 (1993).
Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity," <i>Immunol. Today</i> 15:406-11 (1994).
Edwards et al., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes," Rheumatology 40:205-11 (2001).
Edwards et al., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders," Biochemical Society Transactions 30:824-8 (2002).
Edwards et al., "Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis," Arthritis Rheum. 446:S197 (2002).
Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL," J. Biol. Chem. 273:14363-7 (1998).
Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts," Cell 63:185-94 (1990).
Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory," <i>J. Exp. Med.</i> 180:157-63 (1994).
Foy et al., "Immune regulation by CD40 and its ligand GP39," Annu. Rev. Immunol. 14:591-617 (1996).
 Francisco et al., "In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40," <i>Blood</i> 89:4493-500 (1997).
Fütterer et al., "The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues," <i>Immunity</i> 9:59-70 (1998).
GenBank accession number AF046888
GenBank accession number AF136293
GenBank accession number AK008142
GenBank accession number Al250289, XP002206618
 GenBank accession number Z99716.4, XP002206619
Glennie and van de Winkel, "Renaissance of cancer therapeutic antibodies," <i>Drug Discov. Today</i> 8:503-10 (2003).
Golstein, "Cell death: TRAIL and its receptors," Curr. Biol. 7:R750-3 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	on if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
	Applicant	Anan Chuntharapai et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
(Use several sneets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor," Cell 73:447-56 (1993).
Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-6 (1991).
Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor," Eur. J. Immunol. 23:2631-41 (1993).
Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-83 (2003).
Gorman et al., "B cell depletion in autoimmune disease," Arthritis Res. Ther. 5:S17-21 (2003).
Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," Int. Immunol. 7:1093-106 (1995).
Gray, "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles," <i>Immunology</i> 65:73-9 (1988).
Green and Flavell, "TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation," <i>J. Exp. Med.</i> 189:1017-20 (1999).
Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis," Science 273:1864-7 (1996).
Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," <i>J. Clin. Invest.</i> 109:59-68 (2002).
Gruss and Dower, "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas," <i>Blood</i> 85:3378-404 (1995).
Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth," J. Exp. Med. 188:1185-90 (1998).
Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli," J. Cell. Biochem. (abstract only) Supplement 15F:113 (P424) (1991).
Han et al., "Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers," <i>J. Immunol.</i> 155:556-67 (1995).
Hansen et al., "Genetic profile of insertion mutations in mouse leukemias and lymphomas," <i>Genome Res.</i> 10:237-43 (2000).
Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants," Science 262:1401-7 (1993).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of the form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COI	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> 262:905-7 (1993).
	Hawkins et al., "Selection of phage antibodies by binding affinity: mimicking affinity maturation," <i>J. Mol. Biol.</i> 226:889-96 (1992).
	Higashida et al., "Treatment of DMARD-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
	Hoag et al., "A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15," Immunogenetics 51:924-9 (2000).
	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFq J. Biol. Chem. 264:14927-34 (1989).
	Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis," Agents Actions 19:295-305 (1986)
	Holmes et al., "Structure and functional expression of a human interleukin-8 receptor," Science 253:1278-80 (1991).
	Hoogenboorn et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Mol. Immunol.</i> 28:1027-37 (1991).
·	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5 Mol. Cell 4:563-71 (1999).
	Hymowitz et al., "Structures of APRIL-receptor complexes," J. Biol. Chem. 280:7218-27 (2005).
	Idusogie et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J. Immunol. 164:4178-84 (2000).
	International Search Report for International Application No. PCT/US00/32378, mailed Jun. 11, 2001.
	International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
	International Search Report for International Application No. PCT/US02/23487, mailed Jan. 31, 2006
	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," Cell 66:233-43 (1991).
	Jackson et al., "In vitro antibody maturation: improvement of a high affinity, neutralizing antibody against IL-1β," <i>Immunol.</i> 154:3310-9 (1995).
	Johnson et al., "Expression and structure of the human NGF receptor," Cell 47:545-54 (1986).

	EXAMINER	DATE CONSIDERED
Ì		

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 25, 2003
(Use several sheets if necessary)		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)  Johnson and Chiswell, "Human antibody engineering," <i>Curr. Opin. Struc. Biol.</i> 3:564-71 (1993).  Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mic comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum.</i> 39:797-809 (1996).  Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuving dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).  Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and incorproduction in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).  Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorde <i>Opin. Ther. Targets</i> 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a disciplop and promotes processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i> (2000).	
Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mic comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum</i> . 39:797-809 (1996).  Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuve of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).  Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and inc production in dendritic cells," <i>J. Immunol</i> . 162:2562-8 (1999).  Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorde <i>Opin. Ther. Targets</i> 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," <i>J. Immunol</i> . 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formatio 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a disciplination of the processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).	
comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra," <i>Arthritis Rheum.</i> 39:797-809 (1996).  Josien et al., "TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuve of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).  Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and inc production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).  Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorde <i>Opin. Ther. Targets</i> 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formatio 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a disculop and promotes processing of NF-κB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i>	
of dendritic cells in vivo," <i>J. Exp. Med.</i> 191:495-501 (2000).  Josien et al., "TRANCE, a TNF family member, is differentially expressed on T cell subsets and inc production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).  Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorde <i>Opin. Ther. Targets</i> 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a disciplination of the processing of NF-kB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i>	
production in dendritic cells," <i>J. Immunol.</i> 162:2562-8 (1999).  Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorde <i>Opin. Ther. Targets</i> 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formatio 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discillop and promotes processing of NF-kB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i>	ant properties
Opin. Ther. Targets 7:115-23 (2003).  Kashii et al., "Constitutive expression and role of the TNF family ligands in apoptotic killing of tumo human NK cells," J. Immunol. 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formatio 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," Immunity 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrebed by and promotes processing of NF-kB2," Immunity 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res	duces cytokine
human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999).  Kato et al., "Affinity maturation in Lyn kinase-deficient mice with defective germinal center formatio 160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discretion and promotes processing of NF-kB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i>	rs," Expert
160:4788-95 (1998).  Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class sw germinal center formation," <i>Immunity</i> 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discretion of NF-κB2," <i>Immunity</i> 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," <i>Cancer Res</i>	r cells by
germinal center formation," Immunity 1:167-78 (1994).  Kayagaki et al., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discillop and promotes processing of NF-kB2," Immunity 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res	n," J. Immunol.
loop and promotes processing of NF-kB2," Immunity 10:515-24 (2002).  Kelly et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death," Cancer Res	vitching and
	rete surface
	s. 60:1021-7
Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc Sci. USA</i> 97:3370-5 (2000).	c. Natl. Acad.
Khare and Hsu, "The role of TALL-1 and APRIL in immune regulation," Trends Immunol. 22:61-3 (	2001).
Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnet with complement and immunoglobulin switch variant mediated cytolysis," <i>Leuk. Res.</i> 11:1119-25 (1)	tic beads and 1987).
Kim et al., "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA," J. Methods 156:9-17 (1992).	. Immunol.
Kitson et al., "A death-domain-containing receptor that mediates apoptosis," Nature 384:372-5 (19)	96).
Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring necrosis factor inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-5 (1990).	g tumor

EXAMINER	DATE CONSIDERED
EVALUATED 1 27 1 27 1 27 1 27 1 27 1 27 1 27 1 2	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

EXAMINER		DATE CONSIDERED
	Mandala et al., "Alteration of lymphocyte traffick 296:346-9 (2002).	ing by sphingosine-1-phosphate receptor agonists," Science
	Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063-8 (1990).	
~ <del>-</del>	Maini et al., "Monoclonal anti-TNFα antibody as Immunol. Rev. 144:195-223 (1995).	a probe of pathogenesis and therapy of rheumatoid disease,"
	Madry et al., "The characterization of murine BC factor receptor superfamily," Int. Immunol. 10:16	CMA gene defines it as a new member of the tumor necrosis 593-702 (1998).
	MacLennan, "Germinal centers," Annu. Rev. Im.	munol. 12:117-39 (1994).
	Mackay et al., "BAFF and APRIL: a tutorial on B	cell survival," Annu. Rev. Immunol. 21:231-64 (2003).
	Mackay et al., "Mice transgenic for BAFF develor J. Exp. Med. 190:1697-710 (1999).	op lymphocytic disorders along with autoimmune manifestations,"
	Mackay and Browning, "BAFF: a fundamental s	urvival factor for B cells," Nature Rev. Immunol. 2:465-75 (2002).
	MacFarlane et al., "Identification and molecular Biol. Chem. 272:25417-20 (1997).	cloning of two novel receptors for the cytotoxic ligand TRAIL," J.
	Lotz et al., "The nerve growth factor/tumor necro	osis factor receptor family," J. Leukocyte Biol. 60:1-7 (1996).
	Loetscher et al., "Molecular cloning and express 61:351-9 (1990).	sion of the human 55 kd tumor necrosis factor receptor," Cell
	Locksley et al., "The TNF and TNF receptor sup (2001).	erfamilies: integrating mammalian biology," Cell 104:487-501
	Linsley et al., "Immunosuppression in vivo by a 257:792-5 (1992).	soluble form of the CTLA-4 T cell activation molecule," Science
	Lewis et al., "Cloning and expression of cDNAs demonstrate one receptor is species specific," F	for two distinct murine tumor necrosis factor receptors Proc. Natl. Acad. Sci. USA 88:2830-4 (1991).
-	Levine and Pestronk, "IgM antibody-related poly Neurology 52:1701-4 (1999).	neuropathies: B-cell depletion chemotherapy using rituximab,"
	Lesley et al., "Reduced competitiveness of auto- Immunity 20:441-53 (2004).	antigen-engaged B cells due to increased dependence on BAFF,
	Lentz et al., "Bcmd decreases the life span of B-(1998).	-2 but not B-1 cells in A/WySnJ mice," J. Immunol. 160:3743-7

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
WEST-WEST-WEST-WEST-WEST-WEST-WEST-WEST-		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Marsters et al., "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-кВ," <i>Curr. Biol.</i> 6:1669-76 (1996).
Marsters et al., "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates transcription factors NF-κB and AP-1," <i>J. Biol. Chem.</i> 272:14029-32 (1997).
Marsters et al., "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA," Curr. Biol. 6:750-2 (1996).
Marsters et al., "A novel receptor for Apo2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-6 (1997).
Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3," Curr. Biol. 8:525-8 (1998).
Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," Curr. Biol. 10:785-8 (2000).
Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin-α-deficient mice," <i>Nature</i> 382:462-6 (1996).
Matthews, "Medical heretics," New Scientist 170:34-7 (2001).
Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator," <i>Immunity</i> 8:21-30 (1998).
McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-4 (1990).
McKay et al., "Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population," 69 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology/Associate of Rheumatology Heath Professionals, Oral Presentation #1920 (November 16, 2005).
Mongkolsapaya et al., "Cutting edge: lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL," <i>J. Immunol.</i> 160:3-6 (1998).
Montgomery et al., "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family," Cell 87:427-36 (1996).
Moore et al., "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator," Science 285:260-3 (1999).
Morimoto et al., "Abnormalities in CD4* T-lymphocyte subsets in inflammatory rheumatic diseases," Am. J. Med. 84:817-25 (1988).

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50474/017002
(MODIFIED)		Serial No.	10/626,914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Anan Chuntharapai et al.
		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Mukhopadhyay et al., "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH₂-terminal kinase," J. Biol. Chem. 274:15978-81 (1999).
	Nagata and Golstein, "The Fas death factor," Science 267:1449-56 (1995).
	Nagata, "Apoptosis by death factor," Cell 88:355-65 (1997).
	Nardelli et al., "Synthesis and release of B-lymphocyte stimulator from myeloid cells," <i>Blood</i> 97:198-204 (2001).
	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:6216-21 (1997).
	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>EMBO J.</i> 9:3269-78 (1990).
	Office Action for U.S.S.N. 09/724,341, mailed on June 2, 2003.
	Office Action for U.S.S.N. 09/724,341, mailed on January 30, 2004.
	Office Action for U.S.S.N. 11/069,473, mailed on June 2, 2008.
	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Lett. 424:41-5 (1998).
	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor," FEBS Lett. 431:351-6 (1998).
	Pan et al., "The receptor for the cytotoxic ligand TRAIL," Science 276:111-3 (1997).
	Pan et al., "An antagonist decoy receptor and a death domain-containing receptor for TRAIL," Science 277:815-8 (1997).
	Patel et al., "Engineering an APRIL-specific B cell maturation antigen," J. Biol. Chem. 279:16727-35 (2004).
	Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-9 (1984).
	Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to rituximab," <i>Blood</i> (Abstract 3360) 92(10 Suppl. 1 Pt. 1-2):88b (1998).
	Pitti et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," <i>J. Biol. Chem.</i> 271:12687-90 (1996).
L	

EXAMINER	DATE CONSIDERED
	•

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INTERNATION PION COURT		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> 396:699-703 (1998).
	Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion," <i>Eur. J. Immunol.</i> 18:1397-404 (1988).
	Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients," Scand. J. Immuno. 31:213-24 (1990).
	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> 69:584-91 (1987).
	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor," <i>Nature</i> 325:593-7 (1987).
	Ravetch and Kinet, "Fc receptors," Annu. Rev. Immunol. 9:457-92 (1991).
	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> 83:435-45 (1994).
	Rennert et al., "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth," <i>J. Exp. Med.</i> 192:1677-83 (2000).
	Renshaw et al., "Humoral immune responses in CD40 ligand-deficient mice," J. Exp. Med. 180:1889-900 (1994)
	Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints," <i>Br. J. Rheumatol.</i> 29:84-8 (1990).
	Scapini et al., "G-CSF-stimulated neutrophils are a prominent source of functional BLyS," J. Exp. Med. 197:297 302 (2003).
-	Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," Cell 61:361-70 (1990).
	Schein, "Production of soluble recombinant proteins in bacteria," Bio-Technol. 7:1141-9 (1989).
	Schiemann et al., "An essential role for BAFF in the normal development of B cells through a BCMA-independe pathway," <i>Science</i> 293:2111-4 (2001).
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis," Ger 169:147-55 (1996).
	Schmid et al., "DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant," Proc. Natl. Acad. Sci. USA 83:1881-5 (1986).

EXAMINER	DATE CONSIDERED
EVARABLED: Initial citation considered. Drew line through citation	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Schneider et al., "Characterization of two receptors for TRAIL," FEBS Lett. 416:329-34 (1997).
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> 189:1747-56 (1999).
	Screaton et al., "LARD: a new lymphoid-specific death domain containing receptor regulated by alternative premRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-9 (1997).
	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," Curr. Biol. 7:693-6 (1997).
	Search Report issued by the Eurasian Patent Office for Eurasian Patent Application No. 200400262, mailed April 14, 2005.
	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response," <i>J. Immunol.</i> 148:3093-9 (1992).
	Sheridan et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors," <i>Science</i> 277:818-21 (1997).
	Shields et al., "High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgG1 variants with improved binding to the FcyR*," J. Biol. Chem. 276:6591-604 (2001).
	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-3 (1999).
	Shu and Johnson, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," Proc. Natl. Acad. Sci. USA 97:9156-61 (2000).
	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-19 (1997).
	Smith et al., "T2 open reading frame from the Shope Fibroma Virus encodes a soluble form of the TNF receptor," <i>Biochem. Biophys. Res. Commun.</i> 176:335-42 (1991).
	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death," Cell 76:959-62 (1994).
	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> 73:1349-60 (1993).
	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," Science 248:1019-23 (1990).
	Somer et al., "Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma," Arthritis Rheum. 49:394-8 (2003).
<del></del>	

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains," <i>Proc. Natl. Acad. Sci. USA</i> 94:13069-74 (1997).
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403-10 (1989).
Stamenkovic et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells," <i>Cell</i> 66:1133-44 (1991).
Stasi et al., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura," <i>Blood</i> 98:952-7 (2001).
Supplementary European Search Report for European Patent Application No. 02756618, mailed May 16, 2007.
Tartaglia et al., "Identification and expression cloning of a leptin receptor, OB-R," Cell 83:1263-71 (1995).
Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation," J. Immunol. 135:973-9 (1985).
Tewari and Dixit, "Recent advances in tumor necrosis factor and CD40 signaling," Curr. Opin. Genet. Develop. 6:39-44 (1996).
Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium," <i>J. Immunol.</i> 156:3074-86 (1996).
Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells," <i>J. Immunol.</i> 152:2613-23 (1994).
Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population," <i>J. Exp. Med.</i> 192:129-35 (2000).
Thompson et al., "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," Science 293:2108-11 (2001).
Tuscano et al., "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab," Presented at the Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA (2002).
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope Fibroma Virus genome," Virology 160:20-30 (1987).
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence," <i>Virology</i> 184:370-82 (1991).
Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C," J. Biol. Chem. 264:11282-7 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Valentine et al., "Structure and function of the B-cell specific 35-37 kDa CD20 protein," <u>Leukocyte Typing III</u> , McMichael, Ed., Oxford University Press, pps. 440-3 (1987).
Van Regenmortel, "Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity," <i>Methods</i> 9:465-72 (1996).
Verma et al., "Rel/NF-κB/lκB family: intimate tales of association and dissociation," Gene Dev. 9:2723-35 (1995).
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," EMBO J. 16:5386-97 (1997).
Waldschmidt and Noelle, "Long live the mature B cell – a BAFFling mystery resolved," Science 293:2012-3 (2001).
Wang et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," Nat. Immunol. 2:632-7 (2001).
Ward and Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994).
Ware, "APRIL and BAFF connect autoimmunity and cancer," J. Exp. Med. 192:F35-7 (2000).
Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures," <i>Arthritis Rheum.</i> 28:742-52 (1985).
Wiley et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 3:673-82 (1995).
Wilson et al., "cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions," <i>J. Exp. Med.</i> 173:137-46 (1991).
Wilson et al., "Genomic structure and chromosomal mapping of the human CD22 gene," 150:5013-24 (1993).
Wilson-Rawls et al., "The signal-anchor domain of adenovirus E3-6.7 K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum," <i>Virology</i> 201:66-76 (1994).
Wong et al., "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186:2075-80 (1997).
Wong et al., "TRANCE is a TNF family member that regulates dendritic cell and osteoclast function," <i>J. Leukocyte Biol.</i> 65:715-24 (1999).
Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimers's peptide β/A4," <i>Biochemistry</i> 34:724–30 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation form with the next communication to applicant.	n if not in conformance and not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50474/017002
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/626,914
INTORMATION DIRECT COURT		Applicant	Anan Chuntharapai et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 25, 2003
		Group	1644 .
(37 C.F.R. § 1.98(b))		IDS Filed	August 7, 2008

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
•	Wu and Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem. 262:4429-32 (1987).
	Wu et al., "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS," <i>J. Biol. Chem.</i> 275:35478-85 (2000).
	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nat. Genet. 17:141-3 (1997).
	Xu et al., "Mice deficient for the CD40 ligand," Immunity 1:423-31 (1994).
	Yan et al., "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," Curr. Biol. 11:1547-52 (2001).
	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," <i>Endocrinology</i> 139:1329-37 (1998).
	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor," <i>J. Exp. Med.</i> 169:1747-56 (1989).
	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," Nat. Immunol. 1:252-6 (2000).
	Yun et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40," <i>J. Immunol.</i> 161:6113-21 (1998).
	Zhang et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus," <i>J. Immunol.</i> 166:6-10 (2001).
	Zheng et al., "Induction of apoptosis in mature T cells by tumour necrosis factor," Nature 377:348-51 (1995).

EXAM	IIN	ER
------	-----	----